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ABSTRACT OF THE DISSERTATION 
 
Accelerating the Development of Diagnostic Biomarkers and Mitigating Drugs for 
Radiation Injury with Quantitative Mass Spectrometry 
 
by 
 
Kate Liu 
Doctor of Philosophy in Chemistry 
University of California, Los Angeles, 2019 
Professor Joseph Ambrose Loo, Chair 
 
Nuclear and radiological terrorism is an on-going public health concern, but very few 
effective measures exist to assess the extent of the injury or counter the injuries from these 
potential attacks. In response to this need, the UCLA Center for Medical Countermeasures 
against Radiation (CMCR) has dedicated their research efforts on radiation biodosimetry and drug 
development. On the diagnostic side, existing biodosimetry is only able to provide a crude 
estimate of radiation exposure dose. More effective diagnostic tools are needed to confirm 
exposure and predict tissue-specific radiation injury progression. Towards this end, we aimed to 
develop protein biomarkers that can assess organ-specific radiation damage. Utilizing 
quantitative mass spectrometry (MS)-based proteomics, we performed discovery experiments to 
identify proteins that have desirable biomarker characteristics. In addition, we evaluated a set of 
hypothesized biomarker candidates as part of antioxidant response using a targeted MS method. 
On the treatment side, very few medical products are available to mitigate radiation-induced 
injury. In fact, only three radiomitigators, through drug repurposing, have been approved by the 
FDA for treatment of hematopoietic acute radiation syndrome (H-ARS). The UCLA CMCR has 
iii 
recently identified a novel group of small molecules from high throughput screening (HTS) for 
inhibitors of radiation-induced apoptosis. The lead compound dramatically decreases mortality 
from H-ARS in mice. To elucidate the mechanism of action for the lead compound, we utilized an 
emerging target identification approach based on thermal stability shift upon ligand binding (i.e. 
thermal proteome profiling or TPP). Data from TPP experiments proposed hypothetical targets 
for the lead compound, which can later be validated by protein-ligand binding studies and other 
means.  
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CHAPTER 1: CURRENT STATUS ON MEDICAL PREPAREDNESS FOR 
UNEXPECTED RADIATION EXPOSURE 
The threat of radiological and nuclear terrorism has been an increasing national 
security concern in recent years. Scenarios of concern include dispersion of radioactive 
materials, attacks on nuclear power plants, and the detonation of nuclear weapons.[1] To 
address this concern, the National Institute for Allergy and Infectious Disease (NIAID) has 
established research programs to develop diagnostic tools to assess the levels of 
radiation injury and to develop countermeasure agents for use in the National Strategic 
Stockpile program.[2] A key component of this initiative was the establishment of Centers 
for Medical Countermeasures against Radiation (CMCR), a network of academic 
institutions that drives the research programs. The UCLA CMCR is one of the 4 centers 
in the nation that is dedicated to radiation biodosimetry and drug development research.  
An immediate consequence of ionizing radiation exposure is acute radiation 
syndrome (ARS). There are 3 types of ARS depending on the exposure dose: 
hematopoietic ARS (H-ARS), gastrointestinal ARS (GI-ARS), and cardiovascular/central 
nervous system ARS. H-ARS develops at moderate doses (2-6 Gy) because of the high 
radiosensitivity of progenitor cells. Neurovascular syndrome (>10 Gy) is generally 
considered untreatable due to multi-organ failure at such high levels of exposure.   
Assessment of radiation injury in mass casualty scenarios is not trivial. Radiation 
victims might not initially show clear signs and symptoms of radiation toxicity even if 
exposed to substantial doses of radiation. In addition, there is considerable person-to-
person variability in early and delayed radiation damage to organs and tissues in 
response to a given radiation dose due to factors such as genetic pre-disposition, age, 
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body size, underlying illnesses, and immune status. Therefore, estimates of radiation 
exposure dose alone (i.e. biodosimetry) will not necessarily predict the extent of radiation 
injury to organs and tissues. Traditional biodosimetry relies on detection of chromosome 
abnormality. However, in a mass casualty scenario, cytogenetic assays are not practical 
for diagnostic purposes because the process is time-consuming and requires 
experienced personnel for result interpretation.[3] This assay is also limited to a whole-
body dose estimate, and it can’t properly assess heterogeneous exposure or severity of 
organ damage. Therefore, there is a need for development of radiation-specific 
biomarkers that can confirm exposure and predict acute and delayed radiation injury to 
specific organs and tissues to guide triage and treatment decisions. 
The ideal radiation biomarkers should be measurable in a non-invasive or 
minimally invasive way, sensitive to incremental changes in radiation dose, and give a 
persistent signal (at least 24-hours post exposure). Proteins are highly desirable among 
all forms of molecular biomarkers because they can be accessible from body fluids, 
detectable with high-throughput methods such as mass spectrometry (MS), and most 
importantly, proteins are closely linked to physiological systems. To address the current 
lack of effective radiation biomarkers, we aim to develop and evaluate protein biomarkers 
that can assess organ-specific radiation damage using quantitative mass spectrometry 
techniques. Mass spectrometry has been used for biomarker discovery and validation 
over a decade due to its exquisite analytical specificity.[4] In Chapter 2, a  “shotgun” 
proteomics (discovery-based) experiment is used to identify biomarker candidates and 
pathways that are responsive to radiation. In Chapter 3, a targeted MS method is applied 
3 
to test a biomarker hypothesis based on a key radiation response pathway. This work is 
published in the Journal of Proteomics – Clinical Applications.[5]  
Medical treatment options for radiation victims are currently very limited. Despite 
decades of advances to develop radiation countermeasures for radiation injuries, few 
agents have been FDA approved for ARS.[6,7] The type of countermeasures relevant to 
the context of unexpected radiation exposure is a radiomitigator, which is administered 
after radiation exposure in order to stimulate recovery of injured tissues. Currently 
available medical products have been developed only for treatment of hematopoietic 
ARS, and they are generally cytokines or growth factors such as granulocyte colony-
stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-
CSF).[6,7] These drugs were originally developed for neutrophil stimulation in 
chemotherapy patients and were approved through drug repurposing for treatment of 
radiation victims. Part of the challenge with developing radiation countermeasures is that 
human clinical trials cannot be ethically conducted, and data from animal models have to 
be relied upon to predict human efficacy. To facilitate drug development efforts, the FDA 
passed the Animal Rule in 2002 that specified guidelines and requirements in order to 
use animal data for clinical indications. One of the four requirements is that the 
mechanism of injury and the role of the product towards the reduction of injury have to be 
understood. 
The UCLA CMCR has a theme of discovery and development of novel drugs to 
mitigate acute and chronic radiation syndromes. Recently, CMCR researchers identified 
a group of compounds with a 4-nitrophenylsulfonamide backbone that showed efficacy 
for mitigating hematopoietic ARS.[8] The compounds emerged from in vitro high-
4 
throughput screening (HTS) for inhibitors of apoptosis. Some of these compounds were 
also tested for in vivo efficacy. The lead compound showed broad spectrum mitigation 
effects and anti-tumor action. The mechanism of action for the lead compound needs to 
be elucidated to advance the drug development process. In Chapter 4, a proteome-wide 
approach to target identification is described to discover a molecular mechanism for the 
lead molecule.  
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CHAPTER 2: DISCOVERY OF NEW ORGAN-SPECIFIC BIOMARKERS FOR 
RADIATION INJURY ASSESSMENT 
2.1 Abstract 
With increasing concern about nuclear/radiological terrorism, there is strong interest in 
developing a diagnostic platform to assess radiation injury following an incident. 
Traditional biodosimetry is insufficient for proper diagnosis and prognosis since victims 
may present delayed and/or varied response to radiation. There exists a critical need to 
develop more effective radiation injury biomarkers. To this end, we aim to develop protein 
biomarkers that can monitor organ-specific radiation response in the form of a blood test. 
In this study, we identified panels of candidate biomarkers from mouse bone marrow 
using label-free quantitative proteomics (LC-MSE). C57Bl/6 male mice were sacrificed at 
various time points (2, 4, 8, 30 days) after whole body irradiation and their bone marrows 
were extracted for sample processing and analysis. Over 1800 proteins were identified 
and quantified from LC-MSE data using Progenesis QI for proteomics data analysis. 
Proteins with differential expression after irradiation were classified based on their time 
course expression patterns. For proteins grouped into each temporal pattern, their 
biological functions and pathways were analyzed and compared. Finally, we devised the 
biomarker criteria for “durable” markers with persistent upregulation at later time points 
and for “stochastic” markers showing individual variation in radiation response. Based on 
the criteria, biomarker candidates for potential future investigations were proposed.  
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2.2 Introduction 
The aim of this biomarker discovery project is to identify protein biomarkers in 
tissues and proximal fluids and then seek their presence and verify their expression levels 
in plasma towards the development of a diagnostic blood test for guiding treatment of 
radiation damage. Direct biomarker discovery in blood plasma or serum has not led to 
many successes in the past because of low abundant disease-related proteins in blood. 
Instead, approaches such as using proximal fluid and peripheral tissues can be favorable 
for initial selection of candidates.[9] The tissue protein measurement in this study serves 
as a foundation for potential subsequent investigations of these signatures to be found in 
blood. 
Following radiological or nuclear accidents, hundreds of thousands of people might 
potentially be exposed to radiation. Biodosimetry would help estimate the dose a person 
might have received, and whether the person needs acute care.[10] Biodosimetry is critical 
for both triage and guiding the treatment of exposed population.  Good biomarkers should 
robustly report radiation exposure, and preferably report the damage an individual 
sustained from radiation. Proteins, as part of cellular responses to radiation, are likely 
good indicators of biological damage.  
In this experiment, bone marrow was selected as the target tissue for biomarker 
discovery because death in our mouse model following total body irradiation (TBI) is a 
result of lethal hematopoietic syndrome arising in bone marrow. Tissues were collected 
from control and irradiated mice sacrificed at various time points post 6 Gy TBI. We chose 
the sub-lethal dose of 6 Gy for these studies because it was desirable to avoid animals 
approaching death for our study (LD50/30 for C57 mice is 7.5 Gy).  
7 
2.3 Materials and Methods 
Animals 
C57Bl/6/JAX gnotobiotic male mice were bred and housed in the Radiation 
Oncology AAALAC-accredited animal facility at UCLA, and utilized at a body weight of 
28gms (with 1S.D.<1gm; 9-12wks of age). Mice of both sexes in groups of four were 
matched to minimize variation in strain, age, weight and gender. Animal health was 
monitored at least daily and irradiated mice were followed more closely. Body weight was 
assessed twice per week. Euthanasia was by exposure to isoflurane and confirmed by 
cervical dislocation. There were no deaths due to irradiation or experimental procedures, 
as the dose and times were chosen to avoid hematologic ARS. The experiments were 
approved by the UCLA-IACUC and adhered to all federal and local regulations for the 
humane treatment of animals. 
Irradiation 
Total body irradiation (6 Gy) was performed using an AEC Gamma Cell 40 cesium 
irradiator (Cs-137) within the Animal Facility at a dose rate of around 60 cGy/min on 
unanesthetized mice in a well-ventilated Lucite box. Dosimetry was performed by the 
CMCR Physics Core at UCLA and involved the use of ionization chambers and 
chromographic film to assess beam flatness across the field (<5%). The LD50/30 dose 
for our C57Bl/6 mice is 7.5 Gy (50% animals survive after 30 days).   
Bone Marrow Extraction 
Bone marrow from the unirradiated control mice and irradiated mice after 2, 4, 8, 
and 30 days following 6 Gy TBI were extracted. The bone marrow was flushed from intact 
thigh bones of mice and cleaned with 70% ethanol using 5ml 1X PBS. The resulting bone 
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marrow suspension was centrifuged at 1,000 rpm in a clinical centrifuge and the pellet 
was frozen in a dry ice/ethanol bath and stored at -80°C. 
Proteomic Sample Preparation 
Bone marrow tissue was lysed in 900 µl lysis/reduction/alkylation all-in-one buffer 
containing 0.5% (w/v) sodium deoxycholate, 12 mM N-lauroylsarcosine, 10 mM tris(2-
carboxyethyl)phosphine (TCEP), 40 mM chloroacetamide and 50 mM triethylammonium 
bicarbonate (TEAB). The samples were homogenized with a glass/PTFE Potter-Elvehjem 
tissue grinder using 5-6 hand strokes, followed by heating at 95°C for 5 minutes, and 
ultrasonication (Fisher Scientific Sonic Dismembrator Model 100) with 3 rounds of 10 sec 
bursts on ice. Samples were centrifuged at 16,000 g for 10 min and supernatants were 
collected. Protein concentration in the supernatant was measured using a Pierce BCA 
Protein Assay Kit (reducing agent compatible) following the manufacturer’s protocols 
(Thermo Fisher), and a Shimadzu UVmini-1240 spectrophotometer. An aliquot of 50 μg 
total protein from each sample was diluted 5 fold with 50 mM TEAB. Trypsin (MS grade; 
Thermo Pierce) was added at a 1/100 enzyme to protein ratio and the sample was 
incubated at 37°C for 4 hours, followed by another 0.5 μg of trypsin addition and overnight 
incubation at 37°C. Digestion was quenched by addition of 0.5% trifluoroacetic acid. 
Detergent was removed by ethyl acetate extraction (equal volume to the sample) and the 
mixture was vortexed for 5 min. Samples were centrifuged at 16,000 g for 30 s and the 
top ethyl acetate layer was removed. Samples were dried down and resuspended in 100 
µl Loading Buffer (3% acetonitrile/0.5% acetic acid). The C18/SCX StageTip was 
prepared for each sample by packing a layer of EmporeTM Cation Extraction disk on the 
bottom and a layer of EmporeTM C18 disk on the top in a 200 µl pipet tip. It was conditioned 
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by 100 µl of 100% methanol, C18 Elution Buffer (80% acetonitrile/0.5% acetic acid), 
Loading Buffer (3% acetonitrile/0.5% acetic acid), SCX Elution Buffer (30% 
acetonitrile/500 mM ammonium acetate/0.5% acetic acid) and Loading Buffer, 
respectively. Each conditioning wash was followed by centrifugation at 2000 g for ~30 s. 
The peptide samples were loaded to the C18/SCX spin tips and centrifuged at 2000 g. 
They were washed with 100 µl Loading Buffer, then with 100 µl 3% acetonitrile/500 mM 
ammonium acetate/0.5% acetic acid, and finally with 100 µl Loading Buffer each at 2000 
g for ~30 s. Peptides that did not bind to the SCX filter were collected as the flowthrough 
with 20 µl addition of C18 Elution Buffer. A 20-µl step elution was performed with a syringe 
using the following dilutions of SCX Elution Buffer with varied ammonium acetate 
concentrations at: 17.5 mM, 20 mM, 35 mM, 50 mM, 65 mM, 80 mM, 100 mM, 300 mM, 
and 500 mM. These fractions, including the initial flow-through loading buffer wash, were 
dried down in a SpeedVac and then stored at -80°C until analysis. 
Liquid Chromatography-Mass Spectrometry 
Each fractionated sample was resuspended in 100 µl injection buffer (3% 
acetonitrile, 0.5% acetic acid). For label-free quantification, Waters Hi3 E.coli ClpB 
standard (P63284, 6 synthetic peptide mixture) was spiked in to a 20 µl sample aliquot to 
a final standard concentration of 10 fmol/µl. A pool sample was prepared from an equal 
aliquot from each time point (4 pool samples for each SCX fraction). All samples were 
analyzed in LC-MSE mode on a Waters nanoAcquity UPLC system coupled to a Waters 
Xevo G2-XS mass spectrometer. The samples were grouped by SCX fraction, and 
different time points within the fraction were injected in randomized order. A total of 216 
sample injections were performed (5 time points and 1 pooled sample × 4 biological 
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replicates × 9 SCX fractions). The pooled sample was analyzed at the start and end of 
each block to ensure stability of the LC-MS/MS system. 
A 5-µl partial loop injection was injected into a Waters nanoAcquity UPLC M class 
system with a Symmetry C18 trap column (100 Å pore, 5 µm particle, 180 µm by 20 mm) 
and a HSS T3 analytical column (1.8 µm, 75 µm by 150 mm). Peptides were eluted with 
the following 90 min LC gradient: 7-27% B for the first 55 min, 27-45% B between 55-70 
min, 45-85% B for the next 1 min, 85%B between 71-75 min, ramp down to 5% B for the 
next minute, and equilibrate at 5%B from 76 to 90 min (Solvent A is 0.1% formic acid in 
water, Solvent B is 0.1% formic acid in acetonitrile). Mass accuracy was maintained by a 
lock spray with a GluFiB internal standard peptide (m/z 785.8426). The mass 
spectrometer was operated in LC-MSE sensitivity mode over the m/z 100-2000 range, 
with alternating energies from low CE of 6 V to a high CE between 18-45 V.   
Data Processing 
Raw MS data were imported into Progenesis QI for Proteomics v2.0 with the 
following parameters: lock mass m/z: 785.8426 Da, low energy threshold: 250 cts, 
elevated energy threshold: 100 cts, intensity threshold: 1000 cts, and retention time 
window: automatic. Each SCX fraction was analyzed separately in a single Progenesis 
experiment. Protein identification and quantitation results from all fractions were 
combined in the final analysis. Retention time for samples within each fraction (5 time 
points plus the pool × 4 biological replicates) were aligned automatically based on the 
most suitable reference pool. Peptide ions with charge state greater than 6 were 
excluded. To correct for systematic experimental variation across samples, normalization 
of peptide abundances to the spiked-in ClpB peptides was performed. Peptides were 
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identified by the MSE search against the complete UniProtKB/Swiss-Prot Mus musculus 
database (accessed March 12, 2015, 85247 entries) with added common laboratory 
contaminants and from using the following parameters: trypsin as digest reagent, 500 
kDa protein mass cutoff, maximum 2 missed cleavages, carbamidomethyl cysteine as a 
fixed modification, methionine oxidation as a variable modification, false discovery rate 
(FDR) of 4%, minimum 3 fragment ion matches per peptide, minimum 7 fragment ion 
matches per protein and minimum 1 peptide match per protein. Relative protein 
abundances were calculated from the average of the normalized abundances of three 
most abundant unique peptides (Hi-3 method). Absolute protein quantification was 
obtained based on 50 fmol Hi-3 ClpB calibrant protein (P63284) added. Protein 
measurements were exported for downstream statistical analysis. 
2.4 Results and Discussion 
2.4.1 The LC-MSE label-free experiment 
This LC-MS/MS-based discovery experiment captured time-dependent responses 
of proteins in bone marrow following exposure to ionizing radiation. In this study, C57BL/6 
male mice were exposed to 6 Gy TBI. Unirradiated control mice (n=4) and irradiated mice 
after Day 2, 4, 8, and 30 (n=4 at each time point) were sacrificed, whereby their tissues 
were collected. The bone marrow samples were processed using a standard “shotgun” 
proteomics workflow consisting of tissue homogenization, lysis, protein denaturation, 
tryptic digestion and strong cation exchange (SCX) peptide fractionation prior to mass 
spectrometry analysis. A standard peptide mixture (Hi3 E.coli ClpB protein) was spiked 
into the sample as a calibrant for label-free quantitation. The digested peptide samples 
were analyzed by liquid chromatography with data-independent mass spectrometry using 
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a Quadrupole Time-of-flight (Q-TOF) instrument. In LC-MSE mode, the instrument rapidly 
cycles between a low and high collision energy, so that both peptide precursor ions and 
their fragment ions are simultaneously collected.[11,12] A software platform then matches 
the fragments to their precursors based on mass and LC retention time. This LC-MSE 
label-free experiment achieves quantitation without expensive isotope labeling.  
The mouse work was performed by Elizabeth Singer (UCLA). The mass 
spectrometry sample preparation and data acquisition were performed by a former 
postdoctoral fellow in our lab, Dr. Dyna Shirasaki. My contribution to this project started 
from the MS data processing and analysis.  
Raw MS data were processed using Progenesis QI for Proteomics software. MSE 
peptide ions were searched against the complete the Uniprot Mus musculus database to 
generate peptide and protein IDs. For protein quantitation, the average signals of the top 
3 most intense unique tryptic peptides for each protein were used to represent the protein 
amount. The top 3 quantitation method has been adopted by the community as a label 
free proteomics workflow and it is based on the empirical discovery that the average MS 
signal response for the three most intense tryptic peptides per mole of protein is constant 
with a variation less than 10%.[11] Relative protein concentration to the calibrant was 
computed for each run. With a known amount of Hi-3 ClpB calibrant that was spiked to 
every sample, absolute protein amount was determined. Finally, protein measurements 
were exported for downstream statistical analysis. 
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2.4.2 Global proteome changes after irradiation  
A total of 1844 proteins from mouse bone marrow were identified and quantified 
from the combined LC-MSE data from all SCX fractions using Progenesis analysis. The 
dynamic range of proteins quantified spans 8 order of magnitude.  
By ranking proteins by their abundances, the most abundant ones are proteins 
involved in transcriptional regulation such as histone proteins and zinc finger proteins, as 
well as proteins that play key roles in the regulation of inflammatory process and immune 
response such as Protein S100-A9, a calcium- and zinc-binding protein (Figure 2.1).  
 
Figure 2.1: Proteins sorted by abundance of the pool (combined equal aliquot of 5 time points) in Progenesis QI for 
proteomics. Ankryin-1 protein was highlighted as an illustration, and its time course pattern was displayed at the bottom.  
If proteins are sorted according to different time-course expression profiles, we 
observe early upregulation of DNA damage response proteins such as Protein PML and 
double-stranded DNA repair protein, which peaked at Day 4. We also observe proteins 
involved in DNA repair that peaked at Day 8 such as E3 ubiquitin-protein ligase SHPRH. 
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Lastly, we also see some late-stage DNA damage response factors such as Mediator of 
DNA damage checkpoint protein 1, which elevated at Day 30.  
Recognizing the different time course profiles, we classified these proteins based 
on these four distinct patterns based on their abundances over time (Figure 2.2). 
Examples of proteins that display these patterns are shown in Figure 2.3. Based on these 
patterns, the general biomarker strategy we devised is the following: proteins within each 
pattern were subjected to pathway analysis and these pathways are investigated for their 
relevance in radiation response (Figure 2.4).  
 
Figure 2.2: Differential time course expression patterns and the corresponding percentages of proteins that fell into 
each pattern. Light blue indicates proteins that decreased after radiation exposure and never recovered (42%); orange 
represents proteins that peaked at Day 2 (20%); dark blue represents proteins that peaked between Day 4-8 (19%); 
gold represents proteins that were elevated at Day 30 (13%). 
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Figure 2.3: Protein examples of the 4 time course patterns.  
 
 
Figure 2.4: Biomarker discovery strategy based on time course patterns.  
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2.4.3 Pathway analysis of temporal protein expression patterns 
Proteins were analyzed by PANTHER Gene Ontology (GO) protein classification 
and Ingenuity Pathway Analysis. From GO classification pie charts (Figure 2.5), we can 
see that the predominant biological processes were cellular processes, metabolic 
processes and cellular component organization. If we compare the proportions of these 
processes across the 4 time course patterns, we notice these differences and trends: (1) 
for early responders, there were more proteins classified as biological regulation and 
response to stimulus, which are the expected acute phase response after radiation 
exposure; (2) for mid-to-late phase activation, proteins involved in reproduction started to 
emerge, as cells were attempting to repair the damage after radiation; (3) for down-
regulation, there was a greater portion of cellular component organization or biogenesis 
proteins, which is expected because many bone marrow cells undergo cell death or 
senescence after 6 Gy exposure. The same trends can also be visualized in the bar chart 
displaying the number of proteins that peaked at different time points for each biological 
process (Figure 2.6).  
17 
 
Figure 2.5: Pie chart of PANTHER GO-Slim Biological Process classification of proteins from each of the four time-
course profiles. Asterisks highlights processes that differ in these 4 temporal profiles and they were color-matched to 
highlights in the legend.  
 
Figure 2.6: Bar chart of PANTHER GO-Slim Biological Process of bone marrow proteins at each of the four peak time 
points indicating number of proteins that fell into each category.  
Wnt and Integrin signaling pathways are the key pro-survival radioprotective 
pathways. Interestingly in our pathway analysis, a significant number of proteins were 
mapped to these two signaling pathways (Table 2.1 and 2.2). Wnt signaling pathway is 
well-known for its involvement in tissue regeneration and repair after damage. In the 
context of radiation exposure, there have been many reports on involvement of Wnt 
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signaling in radioresistance and it was recently found that the radioresistance was 
mediated by high-mobility group box 1 protein (HMGB1), a chromatin-associated protein 
regulating DNA repair.[13] Integrin-mediated adhesion to extracellular matrix proteins also 
offers resistance to radiation.[14] Integrins in the cell membrane bind to extracellular matrix 
components and initiate actin reorganization and activation of MAPK and other signaling 
cascades. Pro-survival β1A-integrin/Akt signaling mediated by PI3K was found to be 
critically involved in promoting cell survival after radiation injury.[14]  
Table 2.1: Proteins that were mapped to the Wnt pathway and their time course profiles and fold changes relative to 
unirradiated control mice. 
 
EARLY Day 2/Ctl
Transducin-like enhancer protein 2 1.99
Adenomatous polyposis coli protein 1.80
Inositol 1,4,5-trisphosphate receptor type 2 2.50
Chromodomain-helicase-DNA-binding protein 1-like 7.53
Protein Myh15 2.01
Actin, alpha skeletal muscle 3.44
Myosin-4 1.92
Myosin-8 3.09
Transcription factor 7-like 1 4.55
Myosin-1 1.89
MID Day 4/Ctl Day 8/Ctl
Inositol 1,4,5-trisphosphate receptor type 3 221.54 125.74
Myosin-6 1.91 0.60
Protocadherin-16 2.37 4.45
F-box/WD repeat-containing protein 1A 0.36 7.40
Myosin-7 1.98 0.75
Protein Myh15 2.15 1.47
LATE Day 30/Ctl
Protocadherin-19 9.11
AT-rich interactive domain-containing protein 1A 1.60
Protein Myh13 1.63
F-box/WD repeat-containing protein 1A 16.28
DOWN Day 30/Ctl
Actin, cytoplasmic 1 0.04
Myosin-7B 0.32
MCG140437, isoform CRA_d 0.66
Follistatin-related protein 1 0.26
Inositol 1,4,5-trisphosphate receptor type 1 0.17
Phosphoinositide phospholipase C 0.46
SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin subfamily A member 5
0.40
WNT SIGNALING PATHWAY
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Table 2.2: Proteins that were mapped to the Integrin pathway and their time course profiles and fold changes relative 
to unirradiated control mice. 
 
2.4.4 Bone marrow as a sentinel organ 
For the physiological changes in the mouse as a whole, 6Gy total body irradiation induces 
double-stranded DNA breaks and damage in multiple organs. After TBI, proteins in the 
bone marrow respond to the damage directly in the bone marrow as well as respond to 
signals from the outside (Figure 2.7). Signals from damaged tissues such as lung and gut 
can leak into bloodstream. Cytokines are released into the bloodstream by damaged 
tissues within minutes to hours. These cytokines travel to the bone marrow and enter the 
stem cell niche, which then induces stem cell differentiation and evacuation out of bone 
marrow.  
EARLY Day 2/Ctl
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-
containing subunit alpha
2.06
Alpha-actinin-4 1.89
Actin, alpha skeletal muscle  3.44
Laminin subunit alpha-2 3.34
MID Day 4/Ctl
Alpha-actinin-1 2.36
LATE Day 30/Ctl
Cell division control protein 42 homolog 2.35
Son of sevenless homolog 1 7.88
Laminin subunit beta-3 2.24
Collagen alpha-1(XII) chain 86.66
DOWN Day 30/Ctl
Actin, cytoplasmic 1 0.04
Integrin-linked protein kinase 0.43
Beta-actin-like protein 2 0.40
Collagen alpha-1(III) chain 0.27
Vasodilator-stimulated phosphoprotein 0.46
Basement membrane-specific heparan sulfate proteoglycan 
core protein
0.24
Integrin beta-7 0.33
Protein Col4a6 0.46
Actin-related protein 2/3 complex subunit 5 0.37
Laminin subunit gamma-1 0.00
Alpha-actinin-3 0.57
Collagen type V alpha 3 chain 0.03
Collagen alpha-2(I) chain 0.34
Actin-related protein 2/3 complex subunit 1B 0.46
DOWN WITH RECOVERY Day 30/Ctl
Ras-related C3 botulinum toxin substrate 2 0.52
Integrin alpha-Iib 0.32
INTEGRIN SIGNALLING PATHWAY
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Figure 2.7: Bone marrow responds to damage from inside and outside.  
2.4.5 Proteins with biodosimetry potential 
We established the following criteria for durable and sustainable biomarker 
candidates: greater than 2 fold elevation on Days 4 and 8 (p<0.05). Day 4 and Day 8 were 
selected for two main reasons: bone marrow response within this time window seems to 
be critical to the final survival and recovery of the mice after TBI; these are more realistic 
time points when blood from radiation victims will be screened for diagnosis in a mass 
casualty scenario. Of the 1844 proteins quantified, 156 proteins were found to be elevated 
at least 2 fold at Days 4 and 8. These identified proteins were found to be involved in 
different cellular responses and metabolic processes with functional attributes like DNA 
synthesis, protein synthesis and degradation, apoptosis, oxidative stress. Examples of 
durable biomarker candidates from the Integrin and Wnt signaling pathways are shown 
in Table 2.3.  
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Table 2.3: Examples of durable biomarker proteins in the Integrin and Wnt signaling pathways. 
 
At Day 8, prominent physiological changes in mice were observed: the bone 
marrow appeared pale and thin, the spleen became smaller and fur whitening was also 
observed. Day 8 seems to be a critical transition point in radiation response because we 
observed significant individual variation among the biological replicates. These protein 
abundances at Day 8 might correlate to the stochastic response in mouse survival. A 
simplistic explanation of the differential survival is that in some individuals most 
hematopoietic stem cells are destroyed while in others there are sufficient remaining 
viable stem cells for animal survival beyond 30-days with an apparent recovery from the 
insult.  
Finally, among proteins that fulfilled our general biomarker criteria, we collected a 
panel of proteins with robust up-regulation at 8 days post-TBI, which represents ‘durable’ 
markers of radiation exposure that might predict a stochastic response (Table 2.4). This 
set of proteins is worth further investigation for use in dosimetry.  
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Table 2.4: Biomarker panel for that may be predictive for a stochastic response (greater than 2 fold up-regulation at 
Day 8). 
 
 
 
Protein ID
Peptides 
Total/Unique
Intensity Day 
8/0
Ratio Day 
8/0
Function Role in Disease Pathways Peptides for PRM
Arachidonate 15-
lipoxygenase 
P39654 9/4 0.257/0.016 16.1470016
Enzyme in the 
metabolism 
of polyunsaturate
d fatty acids
 inhibit, limit, and 
resolve diverse 
inflammatory 
diseases
Inflammation mediated by 
chemokine and cytokine 
signaling pathway, 
Gonadotropin releasing 
hormone receptor pathway
DGTILNVAATSISDLPVDQR     
SLDIPYEYLRPSLVENSVAI    
GPGDQGSEYTFPCYR
Alpha-actinin-1
Q7TPR4;A1B
N54;D3YY95;
Q61063;Q99
LJ3
69/19
13.6/5.75 (Day 
4)
2.36 Integrin Signaling
DYETATLSEIK            
LLETIDQLYLEYAKR      
FAIQDISVEETSAKEGLLLWCQR  
Son of sevenless 
homolog 1
Q62245 4/2 1.119/0.475 7.88
Promotes the 
exchange of Ras-
bound GDP by 
GTP. 
Integrin Signaling, EGFR, FGF, 
Inflammation mediated by 
chemokine and cytokine 
signaling pathway, 
Angiogenesis, CCKR Signaling, 
Gonadotropin releasing 
hormone receptor pathway
LDHTFEQIPSR   
QAQQLPYEFFSEENAPK  
Cell division control 
protein 42 homolog
P60766;Q3U
L78
5/3 1.119/.475 2.35
Activated Cdc42 
phosphorylates 
p21-activated 
kinases PAK1 and 
PAK2, which in 
turn initiate actin 
reorganization 
and regulate cell 
adhesion, 
migration, and 
invasion.
 promoting the 
expression of 
β1 integrin which is 
is important for 
adhesion to the 
extracellular matrix
Inflammation mediated by 
chemokine and cytokine 
signaling pathway; Integrin 
Signaling
NVFDEAILAALEPPEPK         
YVECSALTQK
Collagen alpha-
1(XII) chain
Q60847;E9P
X70;Q3TNZ7;
3/1 0.391/0.00452 86.66
Enzyme in the 
metabolism 
of polyunsaturate
d fatty acids
Inflammation mediated by 
chemokine and cytokine 
signaling pathway
NSDVEIFAVGVKDAVR
Laminin subunit 
alpha-2
Q60675;Q5D
TP0
13/3 1.72/.822 2.09
Enzyme in the 
metabolism 
of polyunsaturate
d fatty acids
Integrin Signaling IYFGGLPTLRNLSMK
Inositol 1,4,5-
trisphosphate 
receptor type 3
P70227 4/1 0.254/0.002 125.7
Enzyme in the 
metabolism 
of polyunsaturate
d fatty acids
 inhibit, limit, and 
resolve diverse 
inflammatory 
diseases
Inflammation mediated by 
chemokine and cytokine 
signaling pathway, 
Heterotrimeric G-protein 
signaling pathway-Gq alpha and 
Go alpha mediated pathway, 
Histamine H1 receptor 
mediated signaling pathway,   
Endothelin signaling pathway,  
Gonadotropin releasing 
hormone receptor pathway, 
Wnt Signaling Pathway
FSGMKCSECSR         
IYFGGLPTLRNLSMK   
TAVADNLLFYLGSAK
LIM/homeobox 
protein Lhx2 
P39654 9/4 0.257/0.016 16.1470016
 Gonadotropin releasing 
hormone receptor pathway
SYFAINHNPDAK
Nitric oxide 
synthase, brain 
Q9Z0J4;F8W
GF2;Q9Z0J4-
2;Q9Z0J4-
5;S4R255
3/2 0.342/0.0441 7.76
 Gonadotropin releasing 
hormone receptor pathway, 
CCKR Signaling
   GMNPCPMVLVFGCRQSK    
SSGDGPDLRDNFESTGPLANVR
Ephrin type-A 
receptor 3 
P29319 2/1 11.426/2.886 3.95 Angiogenesis CGWNVRQCEPCSPNVR
Glycogen 
phosphorylase, 
brain 
Q8CI94;Q3TF
Q8;Q3UGT5;
Q3UYH9;Q3
UZL2;Q3V3U
0
24/6 1.703/0.85 2.002
Heterotrimeric G-protein 
signaling pathway-Gi alpha and 
Gs alpha mediated pathway
QAVDQISSGFFSPK              
GYNAREFYER
Regulator of G-
protein signaling 3 
Q9DC04;Q9
DC04-1
2/1 0.1844/0.072 2.53
Heterotrimeric G-protein 
signaling pathway-Gi alpha and 
Gs alpha mediated pathway, 
Heterotrimeric G-protein 
signaling pathway-Gq alpha and 
Go alpha mediated pathway
HSCHLVCDSSDGLLLGGWER
Regulator of G-
protein signaling 7
O54829 1/1 0.213/0.023 9.16
Heterotrimeric G-protein 
signaling pathway-Gi alpha and 
Gs alpha mediated pathway
AFWDVHRPVPGCVNTTEVDIKK
Platelet-derived 
growth factor D 
Q925I7 1/1 3.404/1.0057 3.385 Angiogenesis LTNAVFFPR
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2.5 Conclusion 
Protein markers proposed from bone marrow can be further tested in plasma using 
protein depletion or enrichment strategies prior to mass spectrometry detection. Similar 
biomarker discovery approaches can be applied to other organs like lung or gut to screen 
for organ-specific markers. The overarching goal of this project is to readout an 
individual’s radiation dosimetry and to predict stochastic, organ-specific responses with a 
rapid blood test taken days after radiation exposure.  
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CHAPTER 3: EVALUATION OF BIOMARKER POTENTIAL OF NRF2-MODULATED 
ANTIOXIDANT RESPONSE PROTEINS 
3.1 Abstract 
Potential acute exposure to ionizing radiation in nuclear or radiological accidents presents 
complex mass casualty scenarios that demand prompt triage and treatment decisions. 
Due to delayed symptoms and varied response of radiation victims, there is an urgent 
need to develop robust biomarkers to assess the extent of injuries in individuals. The 
transcription factor Nrf2 is the master of redox homeostasis, as it regulates the basal and 
inducible expression of antioxidant and detoxification genes. Based on prior 
transcriptional evidence of Nrf2-dependent antioxidant response activation upon 
radiation, we investigated the biomarker potential of Nrf2-dependent downstream target 
enzymes by measuring their response in bone marrow extracted from C57Bl/6 and C3H 
mice of both genders for up to 4 days following 6 Gy total body irradiation using targeted 
mass spectrometry. Overall, C57Bl/6 mice have a stronger proteomic response than C3H 
mice. In both strains, male mice have more occurrences of upregulation in antioxidant 
enzymes than female mice. For the more frequently studied C57Bl/6 male mice, 3 
proteins showed elevated abundances after radiation exposure (p<0.01): catalase, 
superoxide dismutase 1, and heme oxygenase 1.  Across both strains and genders, 
glutathione S-transferase Mu 1 was consistently decreased, making it the most promising 
biomarker candidate from our study. 
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3.2 Introduction 
Despite continual risk of radiation from nuclear accidents and terrorist attacks, 
effective assessment of acute radiation exposure remains to be established for triage and 
treatment of the population.[10,15] Following a radiological event, several stages of mass 
screening utilizing a combination of physical and biological dosimetry methods will be 
needed to establish the severity of any radiation exposure. Traditionally, clinical 
determination of radiation dose relies on cytogenetic assays such as chromosome 
aberration, which normally involves lymphocyte cell culture and scoring of abnormalities. 
This process is time consuming and requires experienced personnel, making it unsuitable 
for triage of a mass-casualty event.[3,10,15] In addition, cytogenetic assays from blood 
yields a crude total body dose estimate, which is not ideal given that accidental exposure 
is likely heterogeneous and there is considerable difference in organ sensitivities to 
radiation. On the other hand, protein biomarkers can offer molecular insights into the 
physiology of cells and tissues that can guide organ-specific medical treatment. Despite 
the advantages of proteomics, it has been underutilized in radiation research historically, 
which leads to a scarcity in radiation proteomics knowledge[16] and a shortage of well-
established tissue-specific biomarkers.[17] 
Some of the special challenges for proteomic analysis of radiation biology are due 
to subtle alterations in cell or tissue proteome, even after high dose exposure.[18] This 
impacts the majority of radiation proteomics studies and as a result there has been 
suggestions to apply a fold change cutoff lower than 1.5 for biological significance in 
radiation research.[18] In recent years, applications of proteomics in radiation research 
have increased with advancement in high throughput mass spectrometry technologies. 
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Several groups have developed or implemented state-of-the-art quantitative proteomics 
tools to identify and validate protein biomarker signatures associated with radiation 
exposure.[19–23] Our focus has been on the master regulator of anti-oxidant responses, 
NF-E2-Related Factor 2 (Nrf2). 
Ionizing radiation (IR) causes a multitude of effects on cells. Radiation can directly 
damage DNA and other biomolecules or indirectly through generation of free radicals and 
reactive oxygen species (ROS) leading to acute radiation syndromes (ARS) and chronic 
effects of radiation including carcinogenesis, fibrosis, inflammation, and genomic 
instability.[24,25] In an attempt to maintain redox homeostasis, cellular antioxidant defense 
mechanisms that are composed of small molecular antioxidants and antioxidant enzymes 
are activated. Many antioxidant enzymes are regulated by a key transcription factor, Nrf2. 
Nrf2 is normally sequestered by Keap1 protein in the cytoplasm. Upon activation by 
signals such as ROS, the Nrf2-Keap1 complex is disrupted, leading to nuclear 
translocation of Nrf2 and binding to the Antioxidant Response Element (ARE), which in 
turn regulates expression of downstream antioxidant and detoxification genes that boost 
cell survival.[26] These target genes include glutathione S-transferase (GST), UDP-
glucuronosyltransferases, γ-glutamylcysteine synthetase (γ-GCS), glutathione 
peroxidase, superoxide dismutase 1 (SOD1), heme oxygenase 1 (HO-1), catalase, and 
NADPH: quinone oxidoreductase (NQO-1). These enzymes have been repeatedly 
demonstrated to be cytoprotective against insult, and Nrf2 is assumed to be a key 
regulator for inducible expression of these enzymes.[27,28]    
Two articles published in 2010 reported Nrf2 transcriptional activation following 
ionizing radiation. Tsukimoto et al. showed that low dose gamma rays induced Nrf2 
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activation in mouse macrophage RAW264.7 cells.[29] A separate study by McDonald et 
al. also observed similar Nrf2 induction in different systems.[30] They found that single 
doses of ionizing radiation from 2 to 8 Gy activated ARE-dependent transcription in breast 
cancer cells in a dose-dependent manner. They also observed increased radiosensitivity 
in Nrf2 knock out cells and mice after irradiation.[30] More interestingly, a recent 
transcriptional study by Purbey et al. identified ROS activation of Nrf2 as an important IR 
sensing pathway.[31] Their study reveals that Nrf2 activation by ROS is highly selective to 
radiation exposure as opposed to other environmental insults. In their RNA-Seq data from 
C57Bl/6 bone marrow derived macrophage (BMDM) collected 0.5-24 hr after 6 Gy 
irradiation, only 99 genes (1.1%) were induced more than 4-fold, which is in accordance 
with the common observation of subtle changes in the proteome upon irradiation. Among 
these few potently induced genes, Nrf2-regulated gene expression peaked between 1-2 
hr and were classified as early response genes.  
Besides potent induction of Nrf2 after IR, studies also indicated different induction 
kinetics in different cell types.[32] For example, in the two initial reports, Tsukimoto et al. 
observed a rapid induction in mouse RAW264.7 macrophage cells, whereas McDonald 
et al. found a delayed response of 5 days in other cell types. The different induction 
kinetics can be useful to differentiate the origin of damage. Another factor that can be 
utilized to localize Nrf2 response is isoform-specific tissue distributions. For instance, 
GST enzyme is highly polymorphic and it consists of 25 isoforms in mice and also in 
human (taken from Uniprot). A study mapping out GST tissue distributions in mouse 
reported differential expression of these isoforms in different tissues, and some isoforms 
were predominantly expressed in certain tissues.[33]  
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Therefore, based on the existing evidence of robust and dose-dependent induction 
of Nrf2 following IR and other desirable features such as differential induction kinetics and 
tissue-specific expression, we hypothesized a biomarker potential for Nrf2-mediated 
response proteins in assessment of ionizing radiation exposure and related organ 
damage. Potentially, these proteins can be used towards development of a diagnostic 
blood test for exposure and feedback of efficacy of mitigatory treatment in radiation 
emergencies. 
In this study, using a targeted proteomics approach with mass spectrometry (MS), 
we examined the response of Nrf2-ARE-dependent enzymes in mouse bone marrow 
collected at various time points (8 hours to 4 days) after 6 Gy total body irradiation (TBI) 
in two mouse strains and both genders. The strain and gender groups offer a 
representation of varied radiation response in a population due to different genetic 
backgrounds. Bone marrow is investigated in this initial study because it is a highly 
radiosensitive organ and the responses of the hematopoietic system are major 
determinants of outcome after IR exposure.[34] A high sublethal dose of 6 Gy TBI causes 
significant damage to bone marrow and hematopoietic acute radiation syndrome (H-ARS) 
in mice. Nrf2-mediated response is particularly important in this context because Nrf2 
activation is also known to enhance hematopoietic stem progenitor cell function and 
mitigate IR-induced bone marrow suppression and mortality.[35,36] The measurement of 
Nrf2-ARE-dependent proteins in bone marrow in this study may provide insights to 
hematopoietic recovery of mice and this study serves as a foundation to potential 
subsequent investigations of these signatures in blood. Direct biomarker discovery in 
blood plasma or serum has not led to many successes in the past because of low 
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abundant disease-related proteins in blood. Instead, approaches such as using proximal 
fluid and peripheral tissues can be favorable for initial selection of candidates.[9] 
3.3 Materials and Methods 
Animals 
C3Hf/Sed//Kam and C57Bl/6/JAX gnotobiotic male and female mice were bred and 
housed in the Radiation Oncology AAALAC-accredited animal facility at UCLA, and 
utilized at a body weight of 28gms (with 1S.D.<1gm; 9-12wks of age). Mice of both sexes 
in groups of eight were matched to minimize variation in strain, age, weight and gender. 
Animal health was monitored at least daily and irradiated mice were followed more 
closely. Body weight was assessed twice per week. Euthanasia was by exposure to 
isoflurane and confirmed by cervical dislocation. There were no deaths due to irradiation 
or experimental procedures as the dose and times were chosen to avoid hematologic 
ARS. The experiments were approved by the UCLA-IACUC and adhered to all federal 
and local regulations for the humane treatment of animals. 
Irradiation 
Total body irradiation was performed using an AEC Gamma Cell 40 cesium 
irradiator (Cs-137) within the Animal Facility at a dose rate of around 60 cGy/min on 
unanesthetized mice in a well-ventilated Lucite box. Dosimetry was performed by the 
CMCR Physics Core at UCLA and involved the use of ionization chambers and 
chromographic film to assess beam flatness across the field (<5%). The LD70/30 dose 
for our C3H/Sed mice is 7.73 Gy. For C57Bl/6 mice, it is 8.51 Gy.   
Bone Marrow Extraction 
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At 8 hour, 1, 2 and 4 days after TBI, bone marrow was extracted. The bone marrow 
was flushed from intact thigh bones of mice and cleaned with 70% ethanol using 5ml 1X 
PBS. The resulting bone marrow suspension was centrifuged at 1,000 rpm in a clinical 
centrifuge and the pellet was frozen in a dry ice/ethanol bath and stored at -80°C. 
Proteomic Sample Preparation 
Bone marrow tissue was lysed in 0.5% (w/v) sodium deoxycholate, 12 mM N-
lauroylsarcosine, and 50 mM triethylammonium bicarbonate (TEAB). The samples were 
homogenized with a bead beater (Bullet Blender; Next Advance, Inc.) at max. speed for 
1 min, followed by heating at 95°C for 5 minutes, and sonication in a water bath for 5 min. 
Samples were centrifuged at 16,000 g for 5 min and supernatants were collected. Protein 
concentration in the supernatant was measured using a Pierce BCA Protein Assay Kit 
following the manufacturer’s protocols (Thermo Fisher). An aliquot of 50 μg total protein 
from each sample was reduced with 5 mM tris(2-carboxyethyl)phosphine for 30 min at 
room temperature and alkylated with 10 mM iodoacetamide in the dark for 30 min at room 
temperature. The protein samples were then diluted 5 fold with 50 mM TEAB. Trypsin 
(MS grade; Thermo Pierce) was added at 1/100 enzyme to protein ratio and the sample 
was incubated at 37°C for 3-4 hours, followed by another 0.5 μg of trypsin addition and 
overnight incubation at 37°C. Digestion was quenched by 0.5% trifluoroacetic acid. 
Samples were centrifuged at 16,000 g for 5 min and supernatants were collected and 
dried under vacuum. Samples were desalted with C18 Stagetips made from Empore C18 
solid phase extraction disks. The desalted samples were stored at -80°C until use.  
Surrogate Peptide Selection  
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Proteotypic peptides for Nrf2-modulated proteins were selected from PeptideAtlas 
(www.peptideatlas.org) with preference for high empirical suitability score, number of 
observations and proteotypic score. Peptides were filtered according to the following 
criteria: 8-25 amino acid in length, no missed cleavage site, and no possible modification 
sites such as cysteine, methionine, tryptophan, and N-terminal glutamine. Candidate 
peptides were further evaluated by their performance in Parallel Reaction Monitoring 
(PRM) experiments using a control bone marrow sample. The top 2 peptides were 
selected as surrogates for each protein for the PRM assay (Table 3.1). Peptide 
uniqueness was confirmed by searching against the NCBI Protein Reference Sequence 
database for Mus musculus using BLASTp (exceptions: peptide ITQSNAILR belongs to 
multiple isoforms of GST proteins and peptide YTGTRPSNLAK belongs to multiple 
isoforms of UGT). 
Table 3.1: Protein and surrogate peptides. Peptides with asterisks are not unique to the protein isoform. Bolded 
peptides are the final 6 surrogate peptides used in quantitation.   
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Crude stable isotope-labeled standard (SIS) peptides (13C, 15N on C-terminal R/K) 
for the 18 peptides in Table 3.1 were synthesized by Thermo Pierce. The heavy peptides 
were diluted with injection buffer (3% acetonitrile, 0.1% formic acid) and pooled to make 
a final concentration of either 10 nM or 100 nM in the SIS mixture to match the 
concentrations of endogenous peptides in the sample.  
Liquid Chromatography-Mass Spectrometry 
Each sample was resuspended in 100 µl injection buffer. An equal volume of SIS 
mixture was added to the sample for relative quantitation. All samples were subjected to 
analysis on an Easy-nLC 1000 system coupled to a Q-Exactive mass spectrometer 
(Thermo Fisher Scientific). The samples were grouped into injection blocks that covered 
all conditions of comparison (time points, strains, genders). Each block containing 20 
samples was injected in a randomized order and analyzed in targeted-MS2 mode with 
retention time scheduling (4 min window). Triplicate injections of 8 biological replicates 
were analyzed over 480 runs. An E.coli digest standard (1 μg/μl) was analyzed at the 
start and end of each block to ensure stability of the LC-MS/MS system. 
A 4-µl injection was loaded onto a 75 μm i.d. × 25 cm EASY-Spray analytical 
column (Thermo Fisher Scientific). Peptides were eluted in a 50 min gradient of mobile 
phase A (0.1% formic acid in water) and mobile phase B (0.1% formic acid in acetonitrile) 
at a flowrate of 300 nl/min: 5% B at 0 min, 29% B at 32 min, and 80% B from 40.5-50 min. 
The spray voltage was 2 kV and the capillary temperature was 250 °C. The mass 
spectrometer was operated in a targeted-MS2 acquisition mode with a maximum IT of 
130 ms, 1 microscan, 35 000 resolution, 2E5 AGC target, 1.6 m/z isolation window, and 
27% normalized collision energy.  
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PRM Assay Quantitative Performance 
While 18 peptides were monitored in the assay, the 6 most reliable peptides 
representing 6 proteins were used for final quantitation and these peptides were indicated 
in Table 3.1. Linearity of PRM response for these peptides was evaluated by spiking 
varying amounts of heavy standard peptides into a constant matrix made from pooling 
C57Bl/6 male control mouse bone marrow digest samples, based on the “reverse curve” 
method described in Percy, et al.[37–40] The final heavy peptide concentrations in the pool 
were either 0.05, 0.5, 5, 50, 500 nM or 0.5, 5, 50, 500, 5000 nM depending on the peptide 
(the range was adjusted to match concentrations of endogenous peptides). Triplicate 
injections were performed to construct the reverse response curve. The linear range 
spanned more than four orders of magnitude, and our measurements lay within the linear 
range of the assay (Supplementary Figure S3.1). 
The extent of carryover was also tested by running replicate injections of 4 
randomly chosen samples in different injection orders and compared the peak area ratios 
of target peptides. No significant differences in the peak area ratios between replicates 
were observed, suggesting sample carryover in our LC-MS system was minimal. There 
was also no detectable target peptide in blank runs following sample runs in PRM mode.  
Stable Isotope Label-based Relative Quantification 
Raw PRM data were processed in Skyline (version 3.6.0, MacCoss lab, University 
of Washington). Public MS/MS spectral libraries for Mus musculus were uploaded to 
Skyline from National Institute of Standards and Technology and Global Proteome 
Machine databases. The Uniprot FASTA file for Mus musculus (82124 protein entries) 
was added to Skyline as the background proteome. Extracted chromatograms for target 
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peptides were manually inspected to ensure correct peak detection. Better performing 
peptides with the top three to five transitions were selected for quantification based on 
the higher dot product correlation between the observed transitions of target peptides and 
library spectrum, indicating higher confidence in peptide detection. Summed peak area 
ratios of endogenous versus SIS peptide transitions were obtained for the preliminary 
relative quantification result.  
Statistical Analysis using MSstats 
Statistical analysis was performed with the MSstats package (version 3.6.0) 
implemented in R. Data were divided into 4 groups: C57 male, C57 female, C3H male, 
C3H female. Within MSstats, peak intensities were first log2 transformed, and normalized 
to equalize medians in log2 intensities in all runs within a group of comparison. The 
intensities of the features of a protein in a run were summarized to obtain a single value 
per protein per run, using Tukey’s median polish (accounted for missing values). Finally, 
to test protein abundances for significant changes of each time point compared to 
unirradiated control, a linear mixed effect model was applied and adjusted p-values 
(accounting for multiple comparisons) were obtained.  
3.4 Results and Discussion 
3.4.1 PRM assay development and relative quantification result in Skyline 
Statistical design of mass spectrometry experiments was taken into consideration 
in our assay development.[41] Samples were grouped into randomized injection blocks to 
minimize instrument bias and batch-to-batch variation over month-long data acquisition. 
Within each block, there were 20 samples covering all conditions of comparison, including 
4 mouse groups (two strains and genders) and 5 time points. Samples were analyzed in 
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random order within each block. Eight blocks of biological replicates were cycled three 
times to obtain triplicate measurements.  
With respect to peptide performance in the PRM assay, six out of the nine putative 
protein targets were reliably detected in the biological samples. The remaining three 
proteins had run-to-run inconsistencies either in standard or endogenous peptide levels. 
The Glutathione Peroxidase 1 standard peptides had too much variation in intensity 
between different sample preparations, possibly caused by hydrophobicity issues that 
resulted in variable peptide loss. NAD(P)H dehydrogenase [quinone] 1 and UDP-
glucuronosyltransferase 1-1 endogenous peptides were not reliably detected, possibly 
due to low abundance in this complex matrix. It is conceivable that other more detectable 
peptides exist for these proteins if we relax the peptide selection criteria, but in doing 
quantification accuracy may be compromised. For the final analysis, only one best-
performing peptide per target protein was included and their top 3-5 transitions based on 
dot product and reproducibility were used in quantitation. Summed peak area ratios of 
endogenous versus SIS peptide transitions in Skyline were obtained for visualization of 
the raw relative quantification result (Figure 3.1).  
(a) C57Bl/6 mice 
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(b)  C3H mice 
 
Figure 3.1: Time-dependent antioxidant enzyme response in mouse bone marrow (n=8) following 6 Gy TBI as 
represented by relative peak area ratios of endogenous to SIS peptides obtained from Skyline. (a) C57Bl/6 male (blue) 
and female (orange) mice, (b) C3H male (blue) and female (orange) mice. Error bars indicate standard errors of the 
mean ratios from both biological and technical replicates.  
3.4.2 Statistical significant changes using MSstats 
Skyline data were imported to MSstats in R to test the statistical significance of 
protein abundance changes at each time point relative to the unirradiated controls. Data 
were processed within individual mouse groups. MSstats first log2-transforms and 
normalizes intensities in all runs by equalizing the median intensities of the heavy 
standard peptides. It then generates protein-level summaries for data visualization and 
quality control after imputation for missing values and removal of poor quality features. 
Among the visualization outputs generated in this step, a condition plot displays potential 
systematic differences in protein intensities between conditions (examples shown in 
Figure 3.2). Next, to find differentially abundant proteins, it applies intensity-based linear 
mixed effect models to determine estimate of protein abundance and variation.[42] The 
heatmaps generated from this step provide convenient visualization for strain and gender 
comparisons (Figure 3.3).  
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Figure 3.2: Condition plots for refined protein intensities in bone marrow of C57Bl/6 male mice after 6 Gy TBI. Dots 
indicate the mean of log2 intensities for each time point. Error bars indicate the confidence interval with 0.95 significant 
level for each time point.  
 
 
Figure 3.3: Statistically significance of protein changes in mouse bone marrow at 8 h, Day 1, Day 2, and Day 4 after 6 
Gy TBI compared to unirradiated control in each strain/gender group (n=8). Columns in the heatmaps are comparisons 
of time points relative to control, and rows are proteins. The heatmaps display signed FDR-adjusted p-values using the 
Benjamini and Hochberg approach. Negative sign (blue) indicates down-regulation; positive sign (red) indicates up-
regulation. Brighter color represents stronger differential abundance. Black color represents no significant differential 
abundance.  
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Figure 3.4: Schematic diagram of Nrf2 regulated antioxidants and xenobiotic pathways. The enzymes measured in this 
study are indicated by green boxes. 
3.4.3 Time dependent radiation response in bone marrow 
In general, the time course patterns for these proteins are surprisingly complex 
and reveal progressive changes in the response to radiation in the bone marrow. 
Specifically, the more frequently studied C57Bl/6 male mice showed elevation of CAT and 
HMOX1, a decrease in GSTM1 abundance, a biphasic pattern for SOD1, and no 
prominent change in two GCL subunits (Figure 3.2). With the expectation that higher 
antioxidant capacity is needed for cell survival after irradiation, it is surprising to see 
progressively decreased abundance of GST and GCL enzymes with time given their roles 
in glutathione homeostasis (Figure 3.4), which could be due to their overutilization. In 
contrast, SOD1 and CAT showed a biphasic response that differed in timing between the 
2 mouse strains. For these, a nadir was seen at either 8 or 24 hr for most mouse groups 
(Figure 3.1), which is in keeping with the findings of the Romeo group.[43] This biphasic 
theme that emerged may reflect early and late radiation responses controlled by different 
mechanisms.[32] Cellular responses to radiation are multifaceted and persisting. After an 
initial oxidative insult, a broad range of basal and inducible antioxidant responses is 
39 
initiated as a cytoprotective shield. Following these early events, cells also undergo 
further waves of secondary ROS generation, DNA damage, and signaling. These further 
pro-oxidant responses can persist through multiple cell divisions and manifest differently 
in different subcellular context. Changes of these Nrf2 target enzymes in our time course 
data could potentially represent waves of different signals in the cells and their attempts 
to respond.  
Another layer of complexity comes from different radiation sensitivities in different 
cell types. A high sublethal dose of 6 Gy causes a rapid depletion of cells in the bone 
marrow and peripheral blood.[44] In bone marrow, highly proliferative hematopoietic 
progenitor cells are particularly sensitive and plunge after 6 Gy irradiation, whereas other 
hematopoietic and mesenchymal cells are more resilient. There is also mass immigration 
from bone marrow into the circulation, which profoundly alters its composition. This is 
evident in the color of tissues that ranged from red marrow in control mice to yellow 
marrow in irradiated mice. These changes and subsequent repopulation can potentially 
result in disproportionate shifts in protein levels and be impacted by different basal levels 
of these antioxidant enzymes in various cell types.  
3.4.4 IR-induced alterations in Nrf2-ARE regulated protein targets  
Glutamate-Cysteine Ligase (GCL) enzyme is a heterodimer composed of a 
modifier (GCLM) and a catalytic (GCLC) subunit that catalyzes the first and rate-limiting 
step in glutathione (GSH) synthesis (Figure 3.4). The rate of GSH synthesis is influenced 
by (1) amount and relative ratios of the two GCL subunits, (2) availability of its substrate, 
L-cysteine, and (3) extent of feedback inhibition of GCL by GSH.[45] GCL is predominantly 
regulated by the Nrf2-ARE pathway at the transcriptional level.[45,46] Nrf2 knockout mice 
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showed decreased levels of GCLC and GCLM expression.[46] In our data, we observed 
progressive decreases in abundance of GCLM in C57 F and C3H M&F mice following 6 
Gy irradiation, but no significant change in GCLC levels (Figure 3.3). In most tissues, 
GCLM is thought to be the more rate limiting component and to enhance the catalytic 
ability of GCLC.[47,48] Many laboratories have reported a transcriptional induction in one 
or both of the GCL genes with a wide range of inducers in different cell types.[49] It is 
possible that GCL activity is regulated post-translationally. One study reported that 
treatment of Jurkat cells with ionizing radiation and other model oxidants acutely activated 
GCL without affecting GCLC or GCLM protein levels. The report proposed a mechanism 
of post-translational activation whereby an increased proportion of GCL in the 
holoenzyme form compared to the inactive monomeric form results in high activity and 
GSH production.[50] Another interpretation is that the high level of damage switches the 
redox rheostat towards a pro-oxidant inflammatory response.[32] This second 
interpretation would suggest that this enzyme would be an ideal biomarker for assessing 
damage, and mitigators aimed at increasing its expression would be of value. 
Glutathione s-Transferases (GSTs) are a large family of enzymes that conjugate 
glutathione to electrophilic centers on a wide variety of substances and are therefore 
involved in detoxification of xenobiotics. GSTs are highly polymorphic[51] and different 
variants exist in different tissues.[33] Within the GST superfamily, GST π is known to inhibit 
c-Jun N-terminal kinase (JNK) nonenzymatically to prevent JNK activation and 
apoptosis.[52] Radiation-induced oxidative stress can block this interaction to induce 
apoptosis. GSTM1 can also regulate apoptosis through signal-regulating kinase (ASK1), 
which activates JNK and p38 pathways.[53] Interestingly, in our experiment we observed 
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consistent decreases in GST Mu1 levels across strains and genders. The same pattern 
for GST was also observed in our discovery proteomic experiment from mouse bone 
marrow using the same irradiation treatment, in which GSTM1 and GSTP1 both 
progressively decreased over the course of 30 days after irradiation (data not shown). 
Similar findings for GST radiation response have been reported by other groups. Cholon 
et al. observed an initial decreased level of GST activity and in cytosolic GST pi isoform 
in CHO cells after 4.5 Gy of ionizing radiation.[54] In their study, they only examined π and 
α isoforms of GST and they classified π isozyme as an early response gene to ionizing 
radiation. Adams et al. also found lower in vivo mouse bone marrow GST levels after 2 
Gy.[55] They also discovered that the major changes in GSH and GST occurred in the 
granulocytes of the bone marrow.[55] Based on these results, GST protein is radiation 
responsive and potentially dose-dependent. Furthermore, GST isoforms are tissue-
specific, which suggests it to be a desirable biomarker candidate for tissue-specific 
diagnosis.  
Heme oxygenase 1 (HO-1) is an inducible enzyme that catalyzes degradation of 
heme to biliverdin, CO, and iron. Heme oxygenase is abundant in tissues that degrade 
aged red blood cells, such as the spleen, liver and bone marrow. When red blood cells 
are lysed, free heme is released and can cross cell membranes to cause oxidative 
stress.[56] By breaking down toxic heme, HO plays a critical role in vascular biology, iron 
recycling and cellular protection against oxidative stress.[57] In the context of radiation, 
HO-1 and CO are found to participate in DNA-repair through the ATM protein.[58] In our 
data, HO-1 peaked at Day 1-2 for C57 male mice and Day 2 for C3H male mice (Figure 
3.1). McDonald et al. found a dose-dependent increase in HO-1 mRNA expression as 
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well as protein level in mouse embryonic fibroblast cells irradiated daily with 0.5, 2, or 4 
Gy for 5 days.[30] They further tested in vivo response, in which they also observed a 
significant increase in HO-1 levels in the spleens of C57Bl/6 mice irradiated with 2 Gy 
whole body every 24 hours for 5 days.[30] For HO-1, there seems to be good correlation 
between mRNA expression and protein levels, which suggests the protein level changes 
are primarily caused by transcriptional activation by ionizing radiation.  
Superoxide dismutase (SOD1) and catalase (CAT) work coordinately to 
scavenge and detoxify reactive oxygen species and are essential for antioxidant defense 
in radiation responses. SOD1 converts free radicals to hydrogen peroxide, and CAT then 
breaks down H2O2 to H2O. As such they are involved in apoptosis and cell death. SOD1 
is present in the mitochondria and cytosol of virtually all eukaryotic cells and catalase is 
mostly located in peroxisomes. For these two enzymes, we observed complex wave-like 
patterns in response to radiation. Besides catalase, glutathione peroxidases (GPX) also 
detoxify H2O2, and the relative contribution of CAT and GPX to H2O2 removal is cell type 
and tissue dependent.[59] The relationships between these antioxidants is further 
complicated by induction of SOD1 through pro-inflammatory pathways that could be 
involved in our experiments.[32] 
3.4.5 Gender and strain differences in radiation response 
Both strain and gender differences were detected from our protein measurements.  
It is known that genetic variations in a population contribute to considerable differences 
in radiation response.[60–62] Previously, Wright’s group observed genotype-dependent 
responses in bone marrow from C57Bl/6 and CBA/Ca strains after 4 Gy γ-irradiation;[63] 
they explained the differences in response as a result of different bone marrow 
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macrophage activities, in which CBA/Ca tissue showed damaging inflammatory-type 
response, whereas C57Bl/6 bone marrow showed anti-inflammatory or protective 
response.[64] Taking this diversity in radiation response into account, a consensus has 
been established by the radiation medical countermeasure community to test more than 
one mouse strain in development of radiation protectors and mitigators.[65] Specifically, 
C57Bl/6 and C3H/HeN strains are recommended, for which the most data are available 
and divergence in tissue responses to radiation has been demonstrated.[65] C57Bl/6 mice 
are more radioresistant to hematopoietic ARS than C3H mice, which can be explained by 
more common myeloid progenitor cells in the bone marrow, and in our data they also 
gave a stronger response of Nrf2-regulated antioxidant proteins to 6 Gy TBI.  
A few radiobiology studies have reported gender difference in radiation sensitivity. 
In our study, within each strain, male mice appeared to have more occurrences of 
upregulation of these antioxidant enzymes than female mice. The most prominent 
example is HO-1, in which male mice of both strains showed upregulation in either Day 1 
or Day 2 whereas female mice did not (Figure 3.3). A recent study investigated gender 
differences in genome damage in prepubertal and adult mice following 8 Gy gamma 
radiation using an in vivo micronucleus assay.[66] Irradiation caused higher frequency of 
micronuclei in males of both age groups.[66] Other studies have also shown that male mice 
sustained more radiation damage than female mice given the same exposure.[67,68] Sex 
hormones, particularly estrogen, have been suggested to play a radioprotective role. 
Interestingly, a more fundamental study has looked at the inherent difference in cell death 
programs between the genders.[69] The authors proposed that male mice are more prone 
to PARP-1 necrosis (inflammatory cell death), whereas female mice are more prone to 
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cascade-dependent apoptosis (non-inflammatory cell death) and that estrogen mediates 
this gender-biased cell death.  
The trend of gender difference in radiation sensitivity seems to be translatable from 
mice to human. Although very few clinical studies on gender-specific differences in 
radiation sensitivity are available, a number of epidemiological studies have reported such 
differences in radiation-induced cancer incidence and mortality. In the Life Span Study of 
atomic bomb survivors, women were found to have a significantly lower risk than men in 
development of radiation-associated leukemia.[70] To draw more definitive conclusions 
about gender differences in radiation response, more systematic radiobiological studies 
using various cell or animal models of both genders are needed.  
3.5 Conclusion 
This study reveals time dependent changes in Nrf2-regulated proteins in mouse 
bone marrow following 6 Gy whole body irradiation in representative mouse strains of 
both genders. Despite the complexity of the bone marrow tissue environment, we 
observed some prominent patterns. Among these, the most consistent trend across all 
mouse models is the decreased abundance of glutathione S-transferase Mu1 isoform. 
GSTM1 and related isoforms appear to be promising biomarker candidates and their 
radiation response in blood plasma and dose dependency should be further evaluated. 
Other patterns, including biphasic responses, are strain or gender-specific.  
An ideal radiation injury biomarker should satisfy the following criteria. First, it 
should be readily obtainable (e.g. serum, urine, saliva, sweat); second, the response 
should be radiation dose-dependent; third, it should be persistent during the triage 
timeframe; last, the response should be radiation-specific and not confounded by other 
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stressors. Nrf2-regulated proteins have the potential to fulfill these requirements based 
on previous experimental evidence of robust and dose-dependent activation following IR 
and importance of this pathway in radiation response.[30,31] Beyond the set of Nrf2-
regulated proteins measured in this experiment, other Nrf2-induced proteins are worth 
investigating in future experiments for their biomarker potential, such as the proteins 
encoding the genes that were potently induced in the recent transcriptional study by 
Purbey et al.[31]  
Given that bone marrow is the major blood forming organ, this result can be 
indicative of detectable changes in blood. This study establishes a targeted MS workflow 
and provides the basis for future development of organ-specific protein biomarkers used 
in diagnostic blood test for radiation injury. We acknowledge that these potential markers 
discovered from tissue will be highly diluted once in the blood stream. To target low 
abundance protein biomarkers in blood, antibody enrichment strategies may be needed, 
such as affinity capture of either intact proteins from larger volumes of blood or of peptides 
using peptide-directed antibodies (e.g., Stable Isotope Standards and Capture by Anti-
Peptide Antibodies or SISCAPA).[71] SISCAPA combines the sensitivity of antibody 
enrichment with the specificity of targeted MS detection, offering a solution to bridge 
discovery and validation of biomarkers, which is beyond the scope of the current study. 
Biomarkers for radiation injury not only serves diagnostic or predictive purposes 
for triage, they are also extremely valuable in radiation countermeasure drug 
development, in which typical human clinical trials for radiation is not possible and 
biomarkers are needed to reflect mitigation effects and demonstrate efficacy of new 
drugs.[3] 
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Supplementary Figures  
 
S3.1: Linear response curve by spiking varying heavy standard peptide concentrations in a constant endogenous 
sample matrix consisted of pooled C57Bl/6 male control mice digest samples. The final heavy peptide concentrations 
in the pool were either 0.05, 0.5, 5, 50, 500 nM or 0.5, 5, 50, 500, 5000 nM depending on the peptide (the range was 
adjusted to match concentrations of endogenous peptides). 
Raw data and Skyline data repository access 
Thermo raw files have been deposited to PeptideAtlas with the dataset identifier: 
PASS01319 (http://www.peptideatlas.org/PASS/PASS01319)  
Skyline files have been deposited to Panorama and can be accessed from  
https://panoramaweb.org/pLIaWf.url  
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CHAPTER 4: TARGET IDENTIFICATION OF NOVEL RADIATION MITIGATORS IN 
DEVELOPMENT 
4.1 Abstract 
The limited availability of FDA-approved radiation countermeasures for treatment of acute 
radiation syndrome (ARS) represents a significant unmet medical need. Researchers at 
the UCLA CMCR has recently identified a novel group of small molecule compounds from 
high throughput screening for inhibitors of radiation-induced apoptosis. This group of 
compounds shares a 4-nitrophenylsulfonamide (NPS) backbone. The lead compound not 
only dramatically decreases mortality from hematopoietic ARS in mice, it also provides 
mitigating effect in radiation injury in other tissues. The mechanism of action for the lead 
compound needs to be determined to advance the drug development. To facilitate this 
process, I adopted a thermal proteome profiling (TPP) approach to discover hypothetical 
targets for this drug candidate. TPP is an emerging method in phenotypic-based drug 
discovery that allows for an unbiased search for drug targets on a proteome wide scale. 
TPP is based on the principle that proteins become more resistant to heat upon ligand 
binding. In the first experiment, a conventional TPP method was applied in which cell 
lysates were incubated with the Compound 512 or DMSO control, and then subjected to 
10 temperature treatments. A total of 7322 proteins with thermal stability data were 
obtained from this TPP experiment.  Twelve proteins showed significant melting curve 
shifts according to the criteria set by the original developer of the workflow, and half of 
these proteins showed stabilization by the compound. In the second experiment, a new 
high-throughput approach named Proteome Integral Stability Alteration (PISA) was 
adopted, in which temperature treatments were pooled and the integral stability between 
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control and drug treatment was compared. Since there is no published protocol for PISA 
yet, it is still in exploratory phase. Based on my preliminary data, I discussed some 
considerations in data quality checks and raised concern on reproducibility of these types 
of experiments.  
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4.2 Introduction 
Radiation Countermeasure Development 
Despite the increasing threat of unexpected radiation exposure from terrorism, 
there is a dearth of FDA-approved radiation countermeasures for treatment of acute 
radiation syndrome (ARS). Neupogen (G-CSF) is the first FDA-approved radiomitigator 
to increase survival in patients exposed to myelosuppressive doses of radiation, or 
hematopoietic-ARS.[6] It was approved by the FDA based on animal studies because 
human clinical trials could not be ethically conducted. Later, Neulasta (PEGylated G-CSF) 
and Leukine (GM-CSF) were also approved by the FDA for treatment of H-ARS.[7] All 
three radiomitigators work similarly by accelerating neutrophil recovery, and they are only 
approved for the treatment of the H-ARS subtype.  
Recently, a novel group of small molecule compounds has been identified from 
high throughput screening for inhibitors of radiation-induced apoptosis.[8] The group of 
compounds with 4-nitrophenylsulfonamide (NPS) backbone emerged from in vitro high-
throughput screening (HTS) for inhibitors of apoptosis (Figure 4.1). A compound library 
of 85,000 molecules were screened in pre-irradiated (2 Gy) TIL1 lymphocytic cells that 
are sensitive to radiation apoptosis. Cell viability was assessed comparing drug-treated 
to irradiated control cells. A hit from the in vitro assay is defined as >130% increased 
viability compared to irradiated control. A major group of the top hits from this in vitro 
screening shares the NPS scaffold. Among the 10 NPS compounds shown in Figure 4.1, 
8 of them were tested in vivo, in which the compounds were administered via 
subcutaneous injection to the mice 24 h after 7.725 Gy irradiation (LD70/30) daily for 5 
days. The top 3 hits from in vivo testing are Compounds #3, 4, 5 in Figure 4.1. From the 
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survival plots, we can see these 3 compounds showed significant improvement of survival 
at 3 different dosing levels, contrasting to Compound #1 that showed little efficacy. Among 
these 3 molecules, Compound #5 or 512 is assigned as the lead compound. It is not only 
able to mitigate hematopoietic ARS, but is also effective at mitigating radiation injury from 
other organs such as gut, thorax, and lung. This broad spectrum mitigation effect is highly 
desirable because the current FDA-approved ARS mitigators only act on hematopoietic 
ARS. Moreover, the lead compound has low toxicity and anti-tumor action.  
 
Figure 4.1: In vitro and in vivo results of 4-(nitrophenylsulfonyl)piperazines (NPSP, #1-8) and 4-nitrophenylsulfonamides 
(NPS, #9-10) compounds. In in-vitro screening, compounds were verified as “hits” if they blocked radiation-induced 
apoptosis in an annexin V/PI flow cytometry assay. The data underneath each compound refers to % viability of TIL1 
lymphocytic cells at 24 hrs, compounds being added at 10 μM to TIL1 cells 1 hr after 2 Gy irradiation. Viability was 
assessed by ATPLite production at 24 hrs and is shown relative to 100% of irradiated controls, with >130% (bold) being 
taken as a significant increase. All except #1 and #8 were tested in vivo (bottom graphs). They were injected in 1% 
Cremophor s.c. into C3H male mice (8 per group) starting 24 hrs after 7.725 Gy WBI (LD70/30 estimate), daily for 5 
days. Survival to the day 30 endpoint is expressed using a Kaplan-Meier plot with log rank statistics.[8] 
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Target Identification for Mechanism Elucidation 
The mechanism of action for the lead compound remains to be determined to 
advance the drug development process. There is some evidence suggesting that the drug 
might act through some primitive development pathways such as the Wnt or Hedgehod-
Gli signaling pathway. To uncover the molecular mechanism of the lead compound (512), 
we adopted the thermal proteome profiling (TPP) approach to discover cellular targets for 
this drug candidate. TPP is a proteme-wide target identification approach that is based 
on thermal shift assay. In the Cellular Thermal Shift Assay (CETSA), protein samples are 
heated to a range of temperatures during which they unfold and form aggregates. Ligand 
binding typically stabilizes the protein structure and increases the unfolding temperature, 
hence we observe a right shift in the melting curve with drug treatment (Figure 4.2[72]). 
Early CETSA work uses Western blotting as the readout, which limits the number of 
proteins analyzed in one experiment.[73] CETSA was later combined with multiplexed 
quantitative mass spectrometry into a new workflow, termed Thermal Proteome Profiling 
or TPP (Figure 4.3[74]). Quantitative MS makes it possible to assess thousands of proteins 
in parallel for thermal stability perturbation by ligand binding.  
 
Figure 4.2: Principle of thermal shift assays. Proteins can be thermally stabilized by a ligand, leading to higher apparent 
melting temperature.[72]  
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Figure 4.3: Schematic of a typical TPP experiment with TMT10 labeling. The reporter ion intensities were used to fit 
the melting curve and calculate the melting temperature (Tm) of each protein for vehicle or compound treated 
condition.[74]   
TPP is the first published methodology that allows mass spectrometry-based 
proteome-wide profiling for comprehensive target identification, and it is regarded as a 
major step forward in drug discovery research.[75] Phenotypic screening-based drug 
discovery has been the popular approach in recent decades, whereby large numbers of 
compounds are screened for a desired biological response.[76] This approach has the 
benefit of preserving cellular or organism-based context of protein function, however, they 
require follow-up studies to determine the precise protein target(s) responsible for the 
observed phenotype.[76] The conventional approach to finding target proteins that bind to 
small molecules is affinity purification. Typically in this approach, the compound is 
derivatized and immobilized to a column, and then cell extracts are loaded to the column 
with the expectation that protein targets bind and elute after wash steps. The main caveat 
for this approach is that when the compound is derivatized and bound to a solid support, 
its interaction with the target proteins might be adversely affected. Other challenges with 
affinity based approaches are possible non-specific interactions and loss of true binders 
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due to stringent wash conditions used. As a result, this method works best for high affinity 
ligands binding to abundant targets. More recent affinity based methods have attempted 
to overcome some of these challenges, but they involve additional chemistry reactions 
that add other biases and cost to the process. On the contrary, TPP is an emerging 
approach that avoids compound derivatization and directly monitors a response from 
ligand binding in a physiologically relevant setting. This approach can also be applied to 
living cells besides cell extracts to uncover indirect targets or downstream effects of the 
drug in living cells.  
Two types of TPP experiments were initially proposed by Savitski’s group: TPP-
TR (temperature range) experiment, which is performed over a temperature range at a 
fixed compound concentration, and TPP-CCR (compound concentration range), which is 
conducted at a single temperature over a range of compound concentrations (Figure 
4.4[75]). The TPP-CCR is also known as the isothermal dose-response (ITDR) experiment, 
whereby compound potency can be determined. 
Specifically, in a typical TPP-TR experiment, cells or cell extracts are first treated 
with vehicle or drug. Samples are divided into 10 aliquots and subjected to heating at 
various temperatures (e.g. 37-67°C). Each sample is digested with trypsin and labeled 
with the TMT10 isotope tag. Samples from each condition (vehicle, drug) are mixed prior 
to LC-MS/MS analysis. Protein identification and quantification is performed. Melting 
curves for all quantifiable proteins are generated. Meting points (Tm) for vehicle- and 
drug-treated conditions are compared, and proteins with significantly altered Tm’s are 
identified as potential targets. These targets can be further validated with TPP-CCR 
experiments. In the TPP-CCR experiment, cells or cell lysates are treated with vehicle or 
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drug over 9 concentrations. These 10 samples are subjected to heating at the same 
temperature, which is carefully chosen to include the Tm’s of the potential targets. 
Samples are again digested with trypsin and labeled with TMT10 prior to analysis. After 
protein identification and quantification, dose response curves are fitted and pEC50 values 
(negative log of the concentration at which 50% of the total stabilizing effect has been 
observed) are calculated for proteins whose thermal stability is affected by the drug.  
 
Figure 4.4: TPP experiment schematic. (a) TPP-TR experiment. (b) TPP-CCR experiment.[75]  
In my TPP-TR experiment, I used the software package downloaded from the 
Nature Protocol published by Savitski’s group (Figure 4.5).[75] The first step of the 
workflow is a python package that generates protein ID’s and quantification using Mascot. 
The software merges results from multiple fractions and generates protein level 
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summaries. These summaries are then processed in R to create melting curves and 
identify significant shifts in melting curves primarily based on shifts in Tm’s.  
 
Figure 4.5: Software package for melting curve analysis in TPP experiment.  
To generate melting curves, the fold change of protein abundance at each 
temperature treatment relative to the lowest temperature is calculated, and fitted to a 
sigmoidal curve based on the formula derived from chemical denaturation theory (Figure 
4.6). The critical parameters used for filtering and significance calculations are (1) Tm 
(melting point of a protein), which is defined as temperature at which half of the proteins 
is denatured, and (2) R2, coefficient of determination, which describes how well the fold 
changes fit the melting curve. The software has a cutoff for Plateau (<0.3) and R2 (>0.8) 
values to filter for good quality melting curves. These melting curves are then subjected 
to final 4 requirements for significant shift, and proteins that pass the following criteria are 
the proposed targets from this workflow: 
(1) p-value < 0.1 or 0.2; p-value is computed from z-test with correction for multiple 
testing (Benjamini-Hochberg);  
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(2) melting curves of two replicates should shift in the consistent direction;  
(3) the magnitude of the Tm shift between drug treatment and control should be 
greater than difference between the two control replicates;  
(4) slope has to be steeper than -0.6 (steeper slope is found to give more 
reproducible melting point).  
 
Figure 4.6. Melting curve schematic. Fraction non-denatured is computed from fold change of protein abundance at 
each temperature relative to lowest temperature (e.g. 37°C). These fold changes are fitted to a sigmoidal curve based 
on the formula shown in the upper right insert. Tm is defined as temperature at which half of the proteins are denatured. 
Thermal stability shift is represented by Tm(treatment)-Tm(vehicle).[75] 
In a theoretical TPP-CCR experiment, fold changes at different compound 
concentrations relative to vehicle are computed. These fold changes represent the 
protein’s apparent stability at the specified concentration. A fold change >3/2 is 
designated as stabilization by the compound, and conversely, a fold change <2/3 is 
regarded as destabilization by the compound. If a protein is proposed as a target in a 
TPP-TR experiment, but shows no dose-dependent behavior in a TPP-CCR experiment, 
it is likely a false positive. Another sigmoidal curve formula is used for curve fitting (Figure 
4.7a). In this formula, EC50 is the compound concentration at which the value of the fitted 
curve is 0.5 (Figure 4.7b). Proteins that show significant dose-dependent changes in 
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thermal stability in response to drug treatment are validated as real hits from TPP-TR 
experiments.  
a) 
 
b) 
 
Figure 4.7: TPP-CCR curve fitting formula (a) and dose response curve schematic (b). The temperature should be 
chosen to maximize the offset between vehicle- and compound-treated melting curves in the corresponding TPP-TR 
experiment. The range of concentrations should go from 0 to saturating concentration.[75]  
New TPP Methodology - Proteome Integral Stability Alteration (PISA) 
After early publications of TPP by Savitski’s and Nordlund’s groups, newer TPP 
workflows have arisen in the literature that aims to simplify or streamline this process. 
One promising workflow is the Proteome Integral Stability Alteration (PISA) proposed by 
Zubarev’s lab.[77] Their PISA approach achieves higher throughput and lower cost 
compared to the conventional TPP workflow by pooling all the temperature treatments 
into one combined sample and comparing the “integral” stability between drug and control 
conditions (Figure 4.8, Figure 4.9). By processing the combined sample, this PISA 
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workflow greatly reduces sample preparation complexity and variation. An additional 
benefit of PISA is that it is not dependent on melting curve fitting as for the conventional 
TPP workflow where stringent curve fitting criteria are imposed that results in loss of many 
proteins from being considered for the statistical testing. The number of false negatives 
is potentially reduced using the PISA approach. Because of the predicted increase in 
sensitivity, specificity and throughput of PISA approach, I also performed this PISA 
workflow using the same cell lysates as the conventional TPP experiment, and compared 
the results.  
 
Figure 4.8: Traditional TPP vs. PISA data analysis. (a) TPP-TR melting curve (b) TPP-CCR dose response curve (e)(f) 
PISA data representation, measuring ΔSm as a difference between the integral abundances of the protein in the treated 
and untreated samples (h) Example of a TMT-labeling scheme for a triplicate 2D PISA experiment, where Sm is the 
control sample, Sm’ is drug-treated with saturating drug concentration, Sm” is drug-treated sample with moderate drug 
concentration.[77]  
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Figure 4.9: PISA experiment workflow schematic. Control or drug-treated sample is divided into 10 aliquots and 
subjected to 10 different temperature treatments (top) or drug concentrations (below). The 10 samples are pooled 
before ultracentrifugation and following digestion steps. The two pooled samples are labeled with TMT and fractionated 
prior to LC-MS/MS.[77]   
4.3 Materials and Methods 
4.3.1 Conventional TPP experiment 
Cell Culture and Lysis  
Mouse tumor infiltrating lymphocytes (TIL) cells were grown in RPMI [+] L-
glutamine and additionally supplemented with 10% fetal bovine serum and 1% 100X 
antibiotic antimycotic solution at 37°C, 5% CO2. Approximately 120 million TIL cells were 
harvested for each TPP experiment and washed with PBS. Two biological replicates of 
the TPP experiment came from cells harvested on two different days. The cells were 
suspended in 1.2 ml lysis buffer containing 100mM Tris-HCl, 150mM NaCl, 0.1% NP-40 
(IGEPAL® CA-630, Sigma Aldrich), Roche complete mini Protease inhibitor (1 tablet 
dissolved in 500 µl H2O), and Thermo HALT phophatase inhibitor cocktail (100 µl) on ice. 
The cell suspensions were freeze-thawed 3 times by using liquid nitrogen. The soluble 
fraction was separated from the cell debris by centrifugation at 16,000 g for 10 min at 4 
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C. Protein concentration from the lysate was estimated by the BCA quantitation assay 
(Thermo Pierce).  
Drug Incubation and Heat Treatment 
The cell lysate was diluted with more lysis buffer to a final concentration of ~2mg/ml 
and then divided into 2 aliquots of 594 µl each. One aliquot was treated with 6 µl of DMSO 
and the other was treated with 6 µl of 1 mM Compound 512 (10 µM final concentration). 
After gentle mixing of each tube, they were incubated at room temperature for 30 min.  
After drug incubation, the lysates were further divided into 10 PCR tubes of 55 µl 
aliquots. These 20 aliquots were heated for 3 min on a PCR machine (BioRad C1000 
Touch™ Thermal Cycler) with a temperature gradient setup (37, 41, 44, 47, 50, 53, 56, 
59, 63, 67 °C), followed by a cool down at 4°C for 3 min. The heated cell lysates were 
ultracentrifuged at 100,000 g (48,000 RPM for TLA 100 rotor on a Beckman Coulter 
OptimaTM TLX ultracentrifuge) for 20 min at 4°C, and 45 µl supernatants were collected 
without touching the pellet. Protein concentration of each sample was determined by the 
BCA assay.  
MS Sample Preparation  
Proteins were precipitated by adding 4X volumes of cold acetone (140 µl) and 
cooled for 2 hours at -20°C. The supernatants were removed by centrifugation at 8000 g 
for 10 min. When acetone was mostly dried out, the pellet was resuspended in 100 µl 
membrane compatible buffer containing 50mM triethylammonium bicarbonate (TEAB) 
with 0.5% sodium deoxycholate, and 12 mM sodium lauryl sarcosine. The proteins were 
denatured by sonication for 5 min, followed with heating at 95°C for 5 min. Disulfide bonds 
were reduced by tris(2-carboxyethyl)phosphine (TCEP) to a final concentration of 5 mM 
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at room temperature for 30 min. Cysteine residues were alkylated by iodoacetamide (12.5 
mM final concentration) at room temperature in the dark for 30 min. The sample was 
diluted 5 fold with 50 mM TEAB. Proteins were digested by MS Grade trypsin with a 1:50 
enzyme: protein ratio and incubated at 37°C overnight.  
Peptides were acidified with trifluoroacetic acid (TFA) to a final concentration of 
0.5% and vortexed for 5 min. To each sample, ethyl acetate (1:1 v/v) was added for 
detergent removal and vortexed for 5 min. The mixture was centrifuged at 12,000 g for 
10 min, and the upper organic phase was removed. The ethyl acetate extraction was 
repeated once. Samples were desalted with C18 Micro spin columns (17-170ug capacity, 
Nest Group). Peptide concentration from each sample was determined by a fluorescent 
peptide quantitation assay (Pierce).  
For TMT labeling, peptide samples were resuspended in 100 µl 200mM HEPES 
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 30% ACN. To each TMT10plex 
label, 41 µl ACN was added to dissolve the tags for 5 min with occasional vortexing. Half 
of the sample (50 µl) was labeled with half of the TMT reagent (20 µl). The remaining half 
of sample was stored away. The labeling reaction went on for one hour and was quenched 
with 6 µl 5% hydroxylamine (in 200 mM HEPES) for 15 min, followed by acidification to 
5% formic acid. The 10 samples from control or drugged treatment were combined. The 
two pooled samples were fractionated using the Pierce High pH Reversed-Phase Peptide 
Fractionation Kit following the manufacturer’s protocol. Step elutions of increasing 
acetonitrile concentrations were performed to generate 8 fractions for LC-MS/MS 
analysis.  
Liquid Chromatography−Mass Spectrometry 
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The digested peptides were dried and resuspended in 20 µl 5% formic acid, and 2 
µl was injected onto a 25 cm by 75 µm fused silica capillary column packed in-house with 
bulk C18 reversed phase resin (1.9 µm, 100 Å pore, Dr. Maisch GmbH). A 140-minute 
water-acetonitrile gradient was applied on a Dionex Ultimate 3000 UHPLC system 
(Thermo Fisher Scientific) at a flow rate of 300 nl/min: at 0 min, 1% B; at 5-128 min, 5.5% 
B ramp to 27.5% B; at 135 to 136 min, 35% B ramp to 80% B; hold 80% B till 138 min; 
138.5-140 min, equilibrate to 1% B (Buffer A: water with 3% DMSO and 0.1% formic acid 
and Buffer B: acetonitrile with 3% DMSO and 0.1% formic acid). Peptides were ionized 
by the application of a distal 2.2 kV and introduced into the Orbitrap Fusion Lumos mass 
spectrometer (Thermo Fisher Scientific).  
The Orbitrap Fusion data acquisition method was set to the following: All MS1 
spectra were acquired over m/z 300−1200 in the Orbitrap (120 K resolution at 200 m/z); 
automatic gain control (AGC) was set to accumulate 2E5 ions, with a maximum injection 
time of 100 ms. Data-dependent MS/MS analysis was performed using HCD in the 
Orbitrap. The normalized collision energy was optimized at 35% for HCD. MS2 spectra 
were acquired with a fixed first m/z of 100. The intensity threshold for fragmentation was 
set to 4000, and included charge states 2+ to 6+. A dynamic exclusion of 25 s was applied 
with a mass tolerance of 10 ppm. 
Data Analysis 
Raw data were first processed in Thermo Proteome Discoverer 2.2 for verifying 
TMT labeling efficiency and overall data quality. For actual analysis, raw data were 
processed with the TPP python isobarQuant package (available from GitHub at 
https://github.com/protcode/isob, Python 2.7 was used) and the TPP R package available 
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from Bioconductor (http://bioconductor.org/packages/TPP/). Data were first extracted 
using the python package with the preMascot.py command. TMT isotope interference 
was indicated in the QuantMethod configuration file prior to this step. The FASTA 
database for Mus musculus was downloaded (16,985 Swiss-Prot entries accessed on 
July 25, 2018), and a new FASTA file containing both forward and reverse (decoy) 
sequences was created according to their instructions. Mgf files created from preMascot 
workflow were searched against the combined database using Mascot Daemon with the 
following parameters: cysteine carbamidomethylation and TMT (lysine) as fixed 
modifications, methionine oxidation and TMT (N-term) as variable modifications, max. 2 
tryptic missed cleavages, peptide tolerance of 10 ppm (Mascot version 2.5.1, Matrix 
Science). The searched results (.dat files) were further processed in the postMascot 
workflow. In this step, peptides and proteins were filtered based on a set of criteria such 
as FDR threshold. One good quality peptide was sufficient to infer protein identification. 
Peptide quantification values are corrected for interference caused by co-eluting 
precursors contributing to TMT signal using signal to interference (S2I) ratios.[78] Finally, 
results from 8 high pH fractions were merged to generate protein level summaries for 
each experiment condition (e.g. control, drug treatment). The protein text files are then 
processed using analyzeTPPTR function in TPP R package (version 3.6.0) to generate 
melting curves based on fold changes and to identify statistically significant shifts. 
Analysis of the TPP TR melting curves was described in the Introduction.  
4.3.2 PISA TPP experiment 
Cell Culture and Lysis  
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TIL1 cells were harvested and lysed the same way as the conventional TPP 
method described above. The cell lysate was diluted with more lysis buffer to a final 
concentration of ~2mg/ml and then divided into aliquots. For lysate #1 and #2, lysates 
were split into 3 aliquots of 247.5 µl each and each aliquot was treated with 2.5 µl of 
DMSO, 2.5 µl of 0.1 mM Compound 512 (1 µM final concentration) or 2.5 µl of 1mM 
Compound 512 (10 µM final concentration). For lysate #3, lysate was divided to 4 aliquots 
of 247.5 µl each and the aliquot was treated with 2.5 µl of DMSO, 0.01 mM 512 (0.1 µM 
final concentration), 0.1 mM 512 (1 µM final concentration), or 1 mM 512 (10 µM final 
concentration). After gentle mixing of each tube, they were incubated at room temperature 
for 30 min.  
Drug Incubation and Heat Treatment 
After drug incubation, the lysates were further divided into 10 PCR tubes of 20 µl 
aliquots. These 20 aliquots were heated for 3 min on a PCR machine with a temperature 
gradient setup (37, 41, 44, 47, 50, 53, 56, 59, 63, 67 °C), followed by a cool down at 4°C 
for 3 min. The heated cell lysates were pooled into 150 µl samples and were 
ultracentrifuged at 100,000 g (48,000 RPM for TLA 100 rotor on a Beckman Coulter 
ultracentrifuge) for 20 min at 4°C. After centrifugation, 130 µl supernatants were collected 
without touching the pellet. Protein concentration of each sample was determined by the 
BCA assay.  
MS Sample Preparation  
Proteins were precipitated by adding 4X volumes of cold acetone (480 µl) and 
cooled for 2 hours at -20°C. The supernatants were removed by vacuum centrifugation 
at 8000 g for 15 min. When the acetone was mostly evaporated, the pellet was 
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resuspended in 200 µl membrane compatible buffer containing 50mM triethylammonium 
bicarbonate (TEAB) with 0.5% sodium deoxycholate, and 12 mM sodium lauryl sarcosine. 
The proteins were denatured by sonication for 5 min, followed with heating at 95°C for 5 
min. Disulfide bonds were reduced by tris(2-carboxyethyl)phosphine (TCEP) at room 
temperature for 30 min (5 mM final concentration). Cysteine residues were alkylated by 
iodoacetamide (12.5 mM final concentration) at room temperature in the dark for 30 min. 
The sample was diluted 5 fold with 50 mM TEAB. Proteins were digested by MS Grade 
trypsin with a 1:50 enzyme: protein ratio and incubated at 37°C overnight.  
Peptides were acidified with trifluoroacetic acid (TFA) to a final concentration of 
0.5% and vortexed for 5 min. To each sample, ethyl acetate (1:1 v/v) was added for 
detergent removal and vortexed for 5 min. The mixture was centrifuged at 12,000 g for 
10 min, and the upper organic phase was removed. The ethyl acetate extraction was 
repeated once. Samples were desalted with C18 Micro spin columns (17-170µg capacity, 
Nest Group). Peptide concentration from each sample was determined by fluorescent 
peptide quantitation assay (Pierce).  
For TMT labeling, peptide samples were resuspended in 100 µl 200mM HEPES, 
30% ACN. To each TMT-10 plex label, 41 µl ACN was added to dissolve the tags for 5 
min with occasional vortexing. The labeling reaction went on for one hour and was 
quenched with 8 µl 5% hydroxylamine (in 200 mM HEPES) for 15 min, followed by 
acidification to 5% formic acid. The 10 samples from all 3 biological replicates were 
combined. The pooled sample was desalted with Pierce Peptide Desalting column before 
MS analysis. 
Liquid Chromatography−Mass Spectrometry 
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This TMT10 sample was dried and resuspended in 200 µl 0.1% formic acid/3% 
ACN, and 1 µl was injected into a 15 cm by 75 µm nanoViper C18 column (Thermo). A 
150-minute water-acetonitrile gradient was applied on a Dionex Ultimate 3000 UHPLC 
system (Thermo Fisher Scientific) at a flow rate of 300 nl/min: at 10 min, 0% B; at 11-16 
min, ramp to 7% B; from 16 to 116 min, ramp to 25% B; from 116 to 136 min, ramp to 
60% B; by 137 min, ramp to 95% B; hold at 95% B till 142 min; 143-150 min, equilibrate 
to 3% B (Buffer A: water with 0.1% formic acid and Buffer B: acetonitrile with 0.1% formic 
acid). Peptides were ionized and introduced into the QE plus mass spectrometer (Thermo 
Fisher Scientific).  
All MS1 spectra were acquired over m/z 350−1400 in the Orbitrap (70 K resolution 
at 200 m/z); automatic gain control (AGC) was set to accumulate 3E6 ions, with a 
maximum injection time of 50 ms. Top 15 data-dependent MS/MS analysis was 
performed using HCD in the Orbitrap. The normalized collision energy was optimized at 
30% for HCD. Isolation window was 1.2 m/z. MS2 spectra were acquired with resolution 
of 35 K and a fixed first m/z of 100. The intensity threshold for fragmentation was set to 
10000, and included charge states 2+ to 7+. A dynamic exclusion of 30 s was applied. 
Data Analysis 
Data analysis was performed with Thermo Proteome Discoverer 2.2 using 
workflows recommended by Thermo for a TMT experiment using the QE type of 
instruments. Data was searched against the Uniprot Mus musculus database using 
Sequest HT with TMT6plex (+229.163) and methionine oxidation as dynamic 
modifications and carbamidomethyl as static modification. Data was validated by 
Percolator. For reporter ion quantification, an isotope impurity correction was applied. A 
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co-isolation threshold was set to 50 and an average reporter S/N threshold was 10. 
Intensities were normalized to total peptide amount in each channel so that all TMT 
channels have the same total abundance. The data was analyzed twice with the same 
settings but with a different study design. In one study, individual TMT channels were kept 
as separate abundances, and ratios of each compound-treated channel to their 
corresponding control channel within the same biological replicate set were computed. In 
the other analysis, I used a grouped study design, whereby all samples pertaining to the 
same drug concentrations were combined into a summed abundance and ANOVA p-
values for each group comparison could be obtained.  
4.4 Results and Discussion 
4.4.1 Results from conventional TPP experiment 
Analysis of two sets of biological replicates using the TPP R package (Table 4.1) 
returned a total of 7322 proteins with thermal stability data. Among these proteins, 3720 
(bio rep 1) or 3932 (bio rep 2) proteins passed the melting curve filters (e.g. plateau<0.3 
and R2>0.8) and were used for p-value calculation. As we can see from here, the curve 
fitting filter criteria are quite stringent and about half of the proteins were not considered 
for differential statistical analysis. Eventually, 12 proteins passed the final 4 criteria for 
significant shifts as described previously, and these are the proposed targets from this 
TPP experiment (Table 4.2). Half of the 12 proteins showed stabilization by the compound 
512, whereas the other half presented destabilization.  
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Table 4.1: TPP experiment configuration table in TPP R package. 1 & 2 indicates two biological replicates. 126-131L 
denotes TMT labels and corresponding temperature treatments.  
 
Table 4.2: Proteins with significant melting curve shifts between control and the 512-treated lysates. Blue shaded 
proteins were stabilized by 512 (right shift in melting curve) and yellow shaded proteins were destabilized by 512 (left 
shift in melting curve).  
 
When we take a closer look at the melting curves for the 6 stabilized proteins in 
Figure 4.10, we see that not every proposed target is equally believable although they all 
passed the filters and significance tests. The top 3 proteins in this figure has more 
consistent melting curve profiles between the two biological replicates, whereas the 
bottom 3 proteins showed some anomaly in their melting curve trend that made their 
results appear less reliable.  Based on this result, I performed protein network analysis 
and further functional investigations focusing on the top 3 protein targets: TUSC2, 
SKAP1, and H1F0.  
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Figure 4.10: Melting curves of the 6 proteins that were stabilized by 512. Y-axis is normalized protein abundance fold 
change relative to lowest temperature (i.e. 37°C). Dotted line is control and solid line is drug treated sample. Green and 
purple are two biological replicates. P-value here is taken from one of the two biological replicate comparisons. 
As an initial analysis of the 12 protein targets, I mapped the relationship between 
these proteins using String network analysis tool (Figure 4.11). Besides these 12 proteins 
as input, I added additional interactors that might help with mapping out the associations 
(e.g. Ptprc, Cdk2). String presents a map of protein-protein associations collected from 
experimental data, computational prediction, as well as co-mentioning in literature. Some 
connections start to emerge between the targets, particularly between Skap1 and Histone 
H1. Interestingly, both SKAP1 and histone H1 participate in signaling pathways that 
promote cell proliferation. They are connected through Cdk2, which is a key regulator of 
DNA damage-activated G1-S phase checkpoints.[79]  
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Figure 4.11: String Functional Protein Association Network analysis. A thicker line of connection indicates higher 
confidence of association. Skap1 and H1f0 are actual targets from my experiment (indicated as solid red circles); 
Ptprc and Cdk2 were artificially added as interactors (indicated as dotted red circles).  
These two proteins are both plausible targets for the radiation mitigation drug 
because of their involvement in T cell activation and DNA damage response. Specifically, 
SKAP1 is involved in T cell activation and generates adaptive immune response. After 
ionizing radiation, T cell activation is impaired and T cells are highly sensitive to radiation-
induced injury (they undergo interphase apoptotic death within hours after irradiation).[80] 
CDK levels are normally low in resting T cells, but are increased in G1 phase after upon 
T cell receptor stimulation. Cdk2 is able to phosphorylate Histone H1, which then relaxes 
chromatin structure, and allows the DNA repair complexes to access the site of damage 
(Figure 4.12).[81] Based on this connection between Skap1 and Histone H1, my first 
hypothesis for a mechanism of action is that compound 512 rescues T cell activation and 
stimulates cell proliferation and immune response through a DNA damage response 
pathway.  
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Figure 4.12: Histone H1 compacts chromatin structure.[82] 
Tumor suppressor protein (TUSC2 or Fus1 protein) is another plausible target for 
a radiomitigator. Studies have demonstrated the radioprotective function of this protein 
through maintaining balanced ROS production and mitochondrial homeostasis.[83,84] In 
the first experiment, Fus1-deficient mice were found to suffer from higher radiosensitivity 
manifested in compromised crypt generation in GI tract, and other tissues (Figure 
4.13).[84] This radiosensitivity was later found to be caused by dysregulation of antioxidant 
response by the follow-up experiment.[83] Treatment with inhibitor of pathogenic oxidative 
reactions, pyridoxamine (PM) significantly ameliorated IR-induced damage to the GI 
epithelium in Fus1 KO mice and significantly enhanced survival of irradiated mice (Figure 
4.13).[83] Their experiments also showed that Fus1 KO cells had higher levels of ROS and 
chronic oxidative stress. This is congruent with the fact that mitochondria are a major 
source of ROS following IR leading to chronic injury of the cell (Figure 4.14).[85] This forms 
the basis of my second hypothesis for Compound 512’s mechanism, which is that 512 
targets Fus1 to activate antioxidant response pathways to provide radiation mitigation.  
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Figure 4.13: Morphology of intestinal crypts of wild type and Fus1 KO mice treated to 12 Gy whole body ionizing 
radiation (IR). Last panel is mice treated with PM or pyridoxamine, inhibitor of pathogenic oxidative reactions.[83]  
 
Figure 4.14: IR induces metabolic oxidative stress from generation of RNS and ROS in mitochondria besides direct 
DNA damage.[85]  
4.4.2 Results from PISA TPP experiment 
The original goal to perform additional TPP experiment using the PISA approach 
is to validate the 12 targets I found from the conventional TPP experiment, and discover 
additional hypothetical targets that might be previously eliminated in the stringent curve 
fitting procedure. However, data analysis for PISA experiment is not as straightforward 
as I expected, since PISA is a new methodology and only a proof-of-principle has been 
described in the bioRxiv article.[77] In my opinion, many more iterations of this type of 
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experiments have to be performed to optimize the experiment protocol, experimental 
design and data processing procedure. Here in this early work, I evaluate the 
performance of the instrument and data quality, propose some hypothetical targets based 
on preliminary thresholds, and describe some considerations and challenges associated 
with data analysis.  
To make full use of the TMT10 reagent set, I performed a triplicate of the 2D PISA 
experiment as show in Table 4.3, in which two sets of biological replicates (1,2) were 
treated with two drug concentrations (1 µM and 10 µM), and last set of biological 
replicates (3) were treated with three concentrations (0.1 µM, 1 µM and 10 µM). This 
experimental design is similar to the proposed scheme in the PISA article (Figure 4.9, h). 
Data was acquired on a QE plus platform and analyzed using Thermo Proteome 
Discoverer software version 2.2 (PD 2.2).  
Table 4.3: TMT10 labeling scheme for PISA experiment. 
 
A total of 1951 proteins was identified with high FDR confidence, which is slightly 
lower than the number of proteins identified in unlabeled samples on the same platform 
(range from 2323 to 2794). To look into this issue of relatively low protein ID’s in the TMT 
run, I compared precursor intensity and ion injection time between this TMT run and a 
control sample just prior to TMT labeling. From the PD distribution charts, the TMT run 
had a greater proportion of precursor ions with the lowest intensity level (Figure 4.15). At 
the MS/MS level, the TMT run also had a greater proportion of MS2 ions with maximum 
(100 ms) ion injection time (Figure 4.16). These factors suggest not enough ions were 
accumulated and there is room for improvement in fine-tuning instrument parameters to 
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increase peptide and protein ID, despite using Thermo’s recommended settings for a 
TMT10 experiment on a QE plus.   
 
Figure 4.15: Precursor intensity for TMT 10 labeled sample vs. a control sample prior to TMT labeling analyzed on the 
QE plus.  
 
Figure 4.16: Ion injection time for TMT 10 labeled sample vs. a control sample prior to TMT labeling analyzed on the 
QE plus. 
 In terms of quantitative accuracy, precursor isolation interference is an important 
factor. For the QE instrument, quadrupole isolation window is typically set to 1.6-2 m/z. 
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The QE plus is equipped with Advanced Quadrupole Technology (AQT) that allows more 
efficient ion transmission at narrower isolation width, therefore a narrower window such 
as 0.7 or 1.2 m/z can be selected to reduce number of interference ions that are co-
isolated with the precursor ions in order to improve the reporter ion quantification 
accuracy. In my PISA TMT run on the QE plus, a 1.2 m/z isolation window was selected. 
If we examine the percentages of isolation interferences and compare the different 
isolation windows from the QE, QE plus and Fusion Lumos, we can see that the narrowest 
isolation window on the Lumos yield TMT MS2 data with the least isolation interference 
and best quantitative accuracy (Figure 4.17). In my PD data processing, a default 
threshold of 50% isolation interference was set to eliminate reporter ions with high co-
isolations. Beyond isolation window and ion injection time, all critical instrument 
parameters (resolution, AGC target, collision energy, etc.) have to be carefully selected 
and further optimized to achieve best sensitivity and quantitative accuracy for a TMT 10 
experiment.  
 
 
Figure 4.17: Isolation interference of TMT 10 experiment acquired with 1.6 m/z isolation window on a QE, with 1.2 m/z 
isolation on a QE plus, and 0.7 m/z isolation on a Fusion Lumos. 
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 Ideally what we expect to see from this set of PISA TPP experiments is increased 
summed protein abundance in compound-treated sample compared to control for 
potential targets across all replicates, and also increased response for higher compound 
concentrations (higher abundance in 10 uM compared to 1 uM 512). Based on this 
premise, the most stringent criteria for finding candidate targets would be a significant 
fold change for each of the compound-treated and control pair, that is consistent across 
3 sets of biological replicates. Furthermore, the fold changes should be concentration 
dependent with the strongest differential expression in samples treated with the highest 
compound concentration. In practice, when I subject the data with FC>1 cutoff for each 
pair of comparison (abundance ratio of each compound-treated channel to corresponding 
control channel), only 40 proteins survived. Unfortunately, none of them seem to display 
consistent trends for fold changes across the 3 biological replicates, nor do they display 
consistent behavior for concentration dependency (Figure 4.18). 
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Figure 4.18: Thermo PD display of proteins that have increased abundance in compound treated sample compared to 
control sample in every pair of comparison across the biological replicates and compound concentrations.  Abundance 
ratios of each compound-treated channel vs. control channel are shown on the right side of the table.  
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 To better filter for candidates with more suitable significance threshold, I re-did the 
analysis on the Thermo PD with a grouped experimental design, in which all the replicates 
with the same drug concentrations (DMSO, 0.1 µM, 1 µM, 10 µM) were grouped together 
into an averaged abundance as shown in Figure 4.19 and ratios for these grouped 
abundances were computed along with the ANOVA p-values. From this dataset, I 
generated volcano plots to visualize proteins with significant fold changes. Typically, a p-
value of 0.01 or 0.05 is applied for differential abundance. Here I decided to use a more 
relaxed p-value threshold of 0.1 to capture more potential targets in this early stage. For 
the fold change, I decided to use a cutoff of 1.2 based on the histogram distribution of fold 
changes. With these relaxed thresholds, only 5 proteins passed my criteria (Figure 4.20). 
It is also surprising to see that the lower concentration yielded more significant changes, 
since we expect 10 µM to be the saturating compound concentration that causes a more 
pronounced effect.  
 
Figure 4.19: Grouped study design in Thermo PD. Each channel is labeled with the corresponding type of drug 
concentration, so that the same drug concentrations are combined into group abundances and p-value could be 
computed.  
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Figure 4.20: Volcano plots from Thermo PD that shows differential grouped abundances comparing 10 uM or 1 uM to 
DMSO. The red and green shaded areas indicate significant fold change and p-value. Proteins that pass threshold are 
labeled with their names.  
 Upon closer inspection of the quality of MS data for these 5 proteins, not all of 
them have the same level of confidence in identification and quantification (Table 4.4). 
For example, the top 3 proteins in this table had quite low reporter ion intensities, which 
are close to the reporter ion S/N threshold of 10 set in the analysis. Also, proteins in rows 
2 and 3 had only 1 PSM for identification, making these results less trustworthy.  
Table 4.4: Protein level summary from Thermo PD for the 5 proteins that showed significant fold changes in Volcano 
plots. The upper table shows grouped abundance results; the lower table shows individual abundances from all TMT 
channels.  
 
 
 
Accession Description Coverage [%]# Peptides# PSMs
# Unique 
Peptides # Peptides (by Search Engine): Sequest HT
Abundance 
Ratio: (0p1uM) / 
(DMSO)
Abundance 
Ratio: (1uM) / 
(DMSO)
Abundance 
Ratio: (10uM) / 
(DMSO)
Abundance 
Ratio P-Value: 
(0p1uM) / 
(DMSO)
Abundance 
Ratio P-Value: 
(1uM) / 
(DMSO)
Abundance 
Ratio P-Value: 
(10uM) / 
(DMSO)
P12265 Beta-glucuronidase 1 1 2 1 1 1.349 1.74 1.628 0.00986259 0.024674374
Q91WG2 Rab GTPase-binding effector protein 2 2 1 1 1 1 0.691 1.346 1.039 0.05013193 0.501346477
Q8VE88 Protein FAM114A2 2 1 1 1 1 0.897 1.44 1.337 0.0510534 0.33214671
Q3UDE2 Tubulin--tyrosine ligase-like protein 12 13 6 6 6 6 1.094 1.62 1.105 0.08197686 0.667751942
P61202 COP9 signalosome complex subunit 2 7 3 4 3 3 0.888 1.226 1.117 0.09859094 0.230806798
Accession Description
Abundance: 
F3: 126, 
Control, 
DMSO
Abundance: 
F3: 128N, 
Control, 
DMSO
Abundance: 
F3: 129C, 
Control, 
DMSO
Abundance: 
F3: 127N, 
Sample, 
1uM
Abundance: 
F3: 128C, 
Sample, 
1uM
Abundance: 
F3: 130C, 
Sample, 
1uM
Abundance: 
F3: 127C, 
Sample, 
10uM
Abundance: 
F3: 129N, 
Sample, 
10uM
Abundance: 
F3: 131, 
Sample, 
10uM
Abundance: 
F3: 130N, 
Sample, 
0p1uM
P12265 Beta-glucuronidase 7.8 9.2 9 14.1 13.7 13.1 13.1 13.5 13.5 11
Q91WG2 Rab GTPase-binding effector protein 2 18.3 14.8 15.7 26.2 22.9 18.6 19 17.4 22.6 12.7
Q8VE88 Protein FAM114A2 10.6 10.8 13.7 19.2 16.5 15.2 16.8 11.2 18 11.1
Q3UDE2 Tubulin--tyrosine ligase-like protein 12 120.2 79 115 179 156 110.2 113.9 109.5 148.9 113.9
P61202 COP9 signalosome complex subunit 2 50 39.4 51.1 60.1 57.3 46.2 54.4 52.9 59.3 43.6
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From examining the data, it seems that we need additional QC metrics that are 
more stringent than the default recommended settings for a TMT experiment in Thermo 
PD to filter out poor quality proteins. In my opinion, these metrics can be established 
based on repeated analysis of the sample to see at which level of cutoff the filters can 
generate reproducible protein level results.  Some key metrics to consider are:  
(1) Reporter ion signal to noise ratio  
(2) Isolation interference % 
(3) Precursor ion intensity  
(4) # peptide spectral matches 
(5) # unique peptides per protein 
Lastly, I compared the hypothetical targets found in conventional TPP experiment 
to the PISA experiment results. I searched the 12 protein accessions in this PISA dataset 
and found only 2 of the 12 proteins were also identified here (Table 4.5), and only 1 protein 
had quantification values. Considering the PISA experiment was done using the same 
lysates as the conventional replicates, I would expect more overlap in the result. In reality, 
these two datasets seemed to have a lot of differences in which proteins were identified 
and whether their abundances went up or down upon compound treatment.  
Table 4.5: Previously identified targets that were also found in the PISA data.  
 
4.5 Conclusion 
From the early stage of testing TPP protocols, reproducibility has been a concern. 
For the conventional TPP experiment, the protocol that I created has additional steps to 
Accession Description Coverage [%] # Peptides # PSMs
# Unique 
Peptides # AAs MW [kDa] calc. pI
Score 
Sequest 
HT: 
Sequest 
HT
# Peptides 
(by Search 
Engine): 
Sequest 
HT
# Razor 
Peptides
Abundance 
Ratio: 
(127N) / 
(126)
Abundance 
Ratio: 
(127C) / 
(126)
Abundance 
Ratio: 
(128C) / 
(128N)
Abundance 
Ratio: 
(129N) / 
(128N)
Abundance 
Ratio: 
(130N) / 
(129C)
Abundance 
Ratio: 
(130C) / 
(129C)
Abundance 
Ratio: (131) 
/ (129C)
Q9D0R8 Protein LSM12 homolog 14 3 4 3 195 21.7 7.74 11.16 3 0 0.976 1.037 1.01 1.029 0.952 1.037 0.994
Q9CZB0 Succinate dehydrogenase cytochrome b560 subunit, mitochondrial 5 1 1 1 169 18.4 9.94 2.2 1 0
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solubilize membrane proteins and subsequent detergent removal. It is possible that these 
additional steps introduce more sources of variability between replicate experiments, and 
a very simplified and automated workflow is needed to achieve reproducible results. The 
PISA approach is more simplified since all temperature points are pooled together for 
downstream sample preparation. The main concern here is that the selection of which 
temperature points we choose to combine will affect the extent of the fold changes of the 
targets. Ideally, we would only want to pool the temperatures that generate the biggest 
differences between control and drug-treatment (close to melting point); however, in a 
discovery stage, we don’t know the targets or their melting points in advance. In this first 
PISA experiment, all temperatures from 37 to 67 °C were combined. Perhaps a better 
temperature range is somewhere in between. As the community starts to adopt and 
perform more TPP experiments for target identification, more standard practices will be 
established.  
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